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ABSTRACT
INTERACTIONS AMONG SEX, APOLIPOPROTEIN E GENOTYPE, AND 17-β
ESTRADIOL IN A MOUSE MODEL OF ALZHEIMER’S DISEASE
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Lisa Taxier
The University of Wisconsin-Milwaukee, 2021
Under the Supervision of Professor Karyn Frick
Alzheimer’s disease (AD) is the most common form of dementia, yet its cause remains
a mystery and no truly effective treatments exist. The high incidence of AD, coupled
with its devastating health and economic impacts, highlight the urgent need for
continued research into the etiology of this disease (Ernst & Hay, 1994; Rice et al.,
1993). Although existing and efficacious treatments for AD are lacking, several risk
factors for AD have been identified. One such factor is apolipoprotein E genotype, which
is the greatest genetic risk factor for AD (Ertekin-Taner, 2007; van der Flier et al., 2011).
Another factor is female sex; women comprise almost two-thirds of AD cases
(Alzheimer’s Association, 2021), illustrating a need to understand whether there are sex
and gender-specific risk factors for AD. Importantly, female sex acts synergistically with
APOE4 genotype to increase disease risk (Altmann et al., 2014; Bretsky et al., 1999;
Farrer et al., 1997). Considerable attention has been given to sex steroid hormones
such as the potent estrogen 17-β estradiol (E2) as potential mediators of AD risk in
females, especially given memory decline that coincides with the onset of the
menopausal transition (Jacobs et al., 2016; Paganini-Hill & Henderson, 1996). However,
interactions among sex, E2, and APOE genotype remain poorly characterized, both in
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human patients and in animal models of disease. The overall aim of this dissertation
was to determine whether sex and estrogens influence memory consolidation and
cognition, cell signaling, and dendritic morphology in a mouse model of AD designed to
recapitulate APOE-associated disease risk. To this end, we used male and female
transgenic mice that express 5 familial AD mutations (5xFAD) and human APOE3
(E3FAD) or APOE4 (E4FAD). We first tested 6 month-old male and female E3FAD and
E4FAD mice in a behavioral battery of tasks including object recognition (OR), object
placement (OP), open field (OF), and the Morris water maze, in order to assess whether
female sex and APOE4 genotype act independently or together to increase anxiety-like
behavior and interfere with memory consolidation. We then examined the brains of
these mice to ask whether sex or APOE4 genotype, independently or concurrently,
modulated changes in protein expression or dendritic spine density. Next, we asked
whether gonadal status modulated anxiety-like behavior in female EFADs. Finally, we
asked whether post-training intrahippocampal administration of E2 was of mnemonic
benefit to female E3FADs, E3/4FADs, and E4FADs for object memory consolidation,
and whether this treatment resulted in changes in protein expression or dendritic spine
density in the brains of these mice. Collectively, our results suggest surprisingly few
effects driven by sex alone, or interactions between sex and APOE4 genotype.
However, APOE4 genotype was memory-impairing, associated with decreased spine
density, and altered protein expression relative to APOE3 genotype. Furthermore,
whereas E2 facilitated memory consolidation in ovariectomized E3FAD and E3/4FAD
females, E4FAD females were resistant to the memory-enhancing effects of E2,
including E2 -induced changes in dendritic spine density. Combined, these data add to a
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growing literature implicating APOE4 as a harmful risk factor for AD, and suggest that
E2, and its downstream effectors, may be useful therapeutic targets for individuals not
homozygous for APOE4.
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CHAPTER ONE: Introduction and background
Alzheimer’s disease pathology and symptomology
AD is the leading cause of dementia worldwide (Alzheimer’s Association, 2021).
Patients with AD experience a broad array of symptoms that interfere with daily life, of
which the most prominent is memory dysfunction. Current drugs available to treat AD,
such as acetylcholinesterase inhibitors (e.g. donepezil or galantamine) and NMDA
receptor antagonists (e.g. memantine) provide some symptom management, but do not
reverse the course of disease, which is always fatal (Briggs et al., 2016). The newest
approved drug for AD, aducanumab, is highly controversial and its efficacy for the
cognitive symptomology of disease remains questionable (Phizackerley, 2021; Selkoe,
2019). Due to few efficacious treatment options that often do not substantially modulate
cognition, the behavioral features of AD continue to contribute to poor quality of life for
AD patients. Thus, understanding the mechanisms underlying memory dysfunction in AD
is crucial for the development of better treatment strategies.
Additional behavioral manifestations of AD include increased affective and
emotional dysregulation, which can also severely impair daily functioning (Ferretti et al.,
2001; Porter et al., 2003). Although memory dysfunction is the predominant behavioral
hallmark of AD, anxiety is a frequent comorbidity (Ferretti et al., 2001; Porter et al., 2003).
Indeed, although the primary thrust of much AD research has been to uncover
underpinnings of memory dysfunction, less is known about factors contributing to anxiety
in AD patients. Given the prevalence of anxiety in AD patients (Ferretti et al., 2001), efforts
should be made to include this symptom in disease treatment. Although anxiety may
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result from confusion and distress caused by other cognitive dysfunction, its prevalence
among AD patients underscores that this symptom should not be overlooked.
Apart from cognitive symptomology, AD is characterized by two neuropathological
hallmarks: amyloid plaques and neurofibrillary tangles. These two disease hallmarks were
first described by Alois Alzheimer in 1906 at the 37th Meeting of South-West German
Psychiatrists. During this meeting, Alzheimer reported on a case study of a patient named
Auguste D., whose health he had been monitoring since her admission five years prior to
the Frankfurt Psychiatric Hospital (Cipriani et al., 2011; Stelzmann et al., 1995). Alzheimer
performed an autopsy on the brain tissue of Auguste D. following her death. He described
“military foci…which represented the sites of deposition of a peculiar substance,” which
were later identified as amyloid plaques, as well as fibrils surrounding neuronal cells,
which we now know to be comprised of hyperphosphorylated tau (Cipriani et al., 2011;
Stelzmann et al., 1995).
In the many years since this initial characterization of the AD brain, researchers
have dedicated considerable effort towards understanding whether amyloid deposition
and neurofibrillary tangles are a cause or an effect of AD. Although both of these
neuropathological hallmarks often emerge before cognitive decline is apparent (Price &
Morris, 1999), we lack an understanding of what precipitates amyloid and tau pathology,
as well as the consequences arising from the presence of this pathology in the brain.
Some researchers sit squarely in the amyloid hypothesis camp, some claim that tau
hyperphosphorylation is the culprit of disease pathogenesis, and still others posit that
amyloid and tau work synergistically to promote disease progression. Researchers
arguing that amyloid and tau work together to contribute to disease sometimes use a
2

bullet/trigger analogy; that is, amyloid accumulation, which occurs earlier on, is the trigger,
whereas tau, which forms neurofibrillary tangles later than amyloid plaque formation, is
the bullet (Bloom, 2014). However, the distinct role that each of these pathological
hallmarks plays in disease progression, disease onset, or disease-associated cognitive
symptomology remains elusive. The presence of these hallmarks in non-demented
individuals (Fagan et al., 2009; Morris et al., 2010) also indicates that AD is not
necessarily the cause of, or caused by, these markers. Furthermore, numerous diseasemodifying therapies aimed at reducing amyloid burden or tau hyperphosphorylation have
failed clinical trials (Gauthier et al., 2016), necessitating identification of additional
biomarkers, risk factors, and treatment targets.

The hippocampus and prefrontal cortex in AD
Although AD results in brain-wide dysfunction, learning and memory-related brain
regions such as the hippocampus and the prefrontal cortex (PFC) are often implicated as
major players in AD. The hippocampus is affected early on in disease progression,
identifying this region as a key target for early detection and treatment of disease (Braak
& Braak, 1991). Several landmark postmortem analyses of brains of AD patients revealed
that hippocampal projection neurons were susceptible to cell loss and accumulation of
neurofibrillary tangles in entorhinal cortex (EC) and area CA1 (Braak & Braak, 1991;
Giannakopoulos et al., 1995; Gómez-Isla et al., 1996; Hyman et al., 1984). Layer II of EC
gives rise to the perforant pathway, which is the primary source of cortical-hippocampal
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innervation. Therefore, cell death and pathology in layer II of EC, reported in multiple
studies of postmortem AD brains, suggests compromised hippocampal circuitry.
The PFC is another region implicated in AD progression, although neuropathology
in this region appears later than it does in the hippocampus (Braak & Braak, 1991). The
PFC communicates with limbic structures, including the hippocampus, that are affected
earlier in disease progression (Jay et al., 1989; Verwer et al., 1997), and is susceptible to
age-related declines in gray matter (Raz et al., 1997). Recent work suggests disrupted
connectivity between the hippocampus and PFC in AD patients (L. Wang et al., 2006),
implicating broader network dysfunction in AD patients. Importantly, gene expression
analysis from frontal cortices of AD patients revealed unique clusters of gene expression
changes that preceded AD-associated pathological hallmarks, suggesting that such gene
targets may be well-suited to early interventional treatments for AD (Bossers et al., 2010).
Newly emerging evidence for gene expression changes that occur prior to plaque
deposition and tau accumulation suggests that non-amyloid and tau-targeted
therapeutics, and a focus instead on modulating gene expression, may hold promise for
treatment of AD.

APOE and Alzheimer’s disease
Genetic factors contribute to both early and late-onset AD. Although early-onset AD
has a higher instance of heritability, late-onset AD, which represents the majority of AD
cases, is associated with APOE4 genotype as its predominant genetic risk factor (ErtekinTaner, 2007; van der Flier et al., 2011; Yu et al., 2014). The APOE gene codes for the
4

protein apolipoprotein E, which regulates cholesterol transport in the brain (Leduc et al.,
2010; Poirier, 2005; Weisgraber & Mahley, 1996). Although the estimated prevalence of
allelic differences in APOE differs by ethnicity and geographic location, researchers
estimate that approximately 77.9% of the worldwide population carries the APOE3 allele,
whereas the APOE4 and APOE2 alleles are significantly less prevalent, occurring at an
incidence of 13.7% and 8.4%, respectively (Farrer et al., 1997; Ferri et al., 2005).
Strikingly, the APOE4 genotype contributes to up to 15-fold greater risk of AD than the
more common APOE3 genotype, and even a single copy of the APOE4 allele can magnify
risk by 2-fold (Bertram, 2009; Roses, 1996). Furthermore, over 50% of AD patients carry
the APOE4 allele, whereas only 15% of healthy controls do so (Ward et al., 2012). In
addition to increasing risk for AD, APOE4 also appears to contribute to earlier disease
onset (Corder et al., 1993) and earlier senile plaque accumulation (Kok et al., 2009).
Single and double copies of APOE4 also increased the rate of cognitive decline in AD
patients relative to patients carrying other APOE alleles (Craft et al., 1998; Qian et al.,
2021). Although it is well established that APOE4 worsens disease outcomes and
conveys increased risk for AD relative to other genotypes, the mechanisms through which
it does so remain poorly understood. Although not all AD cases are linked to APOE4
genotype, understanding the root of APOE4-associated disease risk would be of great
benefit to a large portion of individuals affected by AD.
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Female sex as a risk factor for AD
Sex is another major risk factor for AD, such that risk for women of developing AD is
significantly greater than that of men (Nebel et al., 2018). Indeed, women represent two
thirds of AD cases in individuals over age 65 (Andersen et al., 1999; Launer et al., 1999).
This difference in disease prevalence is sometimes attributed to age alone, given
women’s longer life expectancy. However, studies controlling for age find disparities
between sexes that suggest higher disease prevalence among women compared to men.
For instance, even when gender-dependent mortality rates are accounted for, women are
at a two-fold risk of developing AD compared to men (Carter et al., 2012; Viña & Lloret,
2010). Moreover, even at age of 45, the lifetime risk for AD is one in five for women and
one in ten for men (Chêne et al., 2015).
Female sex also contributes to worse cognitive decline relative to male sex in AD
patients. A meta-analysis of several studies including neurocognitive data from patients
with AD revealed that men performed better than their women counterparts on verbal and
visuospatial tasks as well as tests of episodic and semantic memory (Irvine et al., 2012).
These data are consistent with other findings that female sex exacerbates cognitive
decline relative to male sex in AD patients, in one instance to a similar magnitude as
APOE4 genotype alone (Holland et al., 2013). Furthermore, the relationship between
global AD pathology and clinical diagnosis is stronger in women than in men (Barnes et
al., 2005), suggesting that AD pathology may be more closely linked to dementia in
women than in men. Thus, examining the contributions of sex and gender to AD etiology
is critical for our overall understanding of the disease.
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APOE and sex interactions
Perhaps unsurprisingly, sex and APOE genotype interact to promote risk for AD.
Female APOE4 carriers are more likely than male APOE4 carriers to develop AD,
suggesting a sex by genotype interaction (Altmann et al., 2014; Bretsky et al., 1999;
Farrer et al., 1997; Kim et al., 2009). In support, APOE genotype correlates strongly with
pathological and behavioral hallmarks of AD, more so in women than in men. For
example, levels of total and phosphorylated tau protein in cerebrospinal fluid were more
strongly associated with APOE4 genotype in women carriers than in male carriers
(Altmann et al., 2014; Hohman et al., 2018). APOE4 was also coupled more strongly to
cognitive decline in women than in men (Hobel et al., 2019; Mortensen & Høgh, 2001).
Indeed, two copies of APOE4 conferred a larger negative impact on women than on men,
resulting in poorer global cognition between the ages of 70-74, and worse memory
between the ages of 65-69 (Hobel et al., 2019). Ultimately, understanding why APOE4
genotype is particularly detrimental to women carriers is of central importance to
developing new approaches for AD prevention and treatment.

Molecular correlates of Alzheimer’s disease
Studying the molecular correlates of AD is uniquely challenging. Both normal cognitive
aging and pathological aging lead to cognitive decline. Moreover, many other dementiacausing illnesses exist, multiple of which are also characterized by misfolded proteins as
in AD (Agorogiannis et al., 2004; Sweeney et al., 2017). Thus, differentiating ADassociated mechanisms from normal aging or other dementias can be difficult. Significant
7

progress has been made with the advent of imaging approaches such as amyloid and tau
PET, and ongoing searches for early biomarkers of disease will hopefully yield additional
methods of early diagnosis and intervention. Despite the challenges associated with
identifying molecular correlates specific to AD, researchers have made significant
progress towards understanding what molecular changes occur in the brains of
individuals with AD, mostly via postmortem tissue analyses.
Synaptic dysfunction is a principal component of AD pathology that underlies ADassociated cognitive decline (DeKosky & Scheff, 1990; LaFerla & Oddo, 2005). AD
patients experience both pre- and post-synaptic protein loss, particularly in the neocortex
and hippocampus, brain regions selectively vulnerable to both AD pathology and neuronal
loss (Masliah et al., 2001; Reddy et al., 2005). Increased synaptic protein loss has been
linked to APOE4 genotype (Tannenberg et al., 2006), and decreased dendritic spine
density in APOE4+ individuals mirrors similar decreases in synaptic proteins (Dumanis et
al., 2009; Ji et al., 2003). Because excitatory signaling is thought to be localized to
dendritic spines, AD-related reductions in dendritic arborization and spine density
substantially diminish excitatory synaptic plasticity and impair cognition (Herms &
Dorostkar, 2016). However, few studies have directly compared the influences of sex and
APOE4 genotype in combination on synaptic protein levels and spine morphology.
Indeed, the influence of sex alone on synaptic protein levels and spine morphology in AD
patients and mouse models remains unclear, although existing studies suggest synaptic
integrity is reduced in females (Jiao et al., 2016; Rijpma et al., 2013). Thus, whether the
negative impact of APOE4 on synaptic integrity and dendritic spine density is exacerbated
by female sex remains unclear.
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Mitogen associated protein kinase (MAPK) signaling through phosphorylated
extracellular signal regulated kinase (pERK) facilitates hippocampus-dependent learning
and memory (Atkins et al., 1998; Selcher et al., 1999), making it an appealing target for
cognitive therapeutics targeting memory dysfunction. Moreover, MAPK signaling
interfaces with many other signaling cascades such as phosphatidylinositol 3-kinase
(PI3K) and c-Jun N-terminal kinase (JNK) within the hippocampus to enhance memory
consolidation in both males and females (Koss & Frick, 2017; Sherrin et al., 2011). MAPK
signaling dysfunction has also been linked to AD, although it has received comparatively
little attention within the field of AD research relative to other molecular events (Pei et al.,
2002). Previous work indicates that MAPK signaling is differentially affected by APOE
genotype (Salomon-Zimri et al., 2019) and by sex (Koss et al., 2018). Elucidating whether
these memory-related signaling pathways are modulated by APOE genotype and sex
may yield important insights into the pathogenesis of memory dysfunction in AD.
In addition to aberrant synapse and cell signaling, neuroinflammation has long been
observed to be an early symptom in AD pathology, driven by both astrogliosis and
microgliosis (Heneka et al., 2015). Importantly, female mice have significantly higher
numbers of both astrocytes and microglia relative to male mice, and this cell population
increases with age (Mouton et al., 2002). Moreover, microglia-specific gene expression
markedly differs by sex in the aged mouse hippocampus (Mangold et al., 2017). Yet, as
with synaptic integrity and intracellular signaling, little is known about how glial activation
in the AD brain is modulated by female sex and APOE4 genotype in concert.

9

Estrogens as a modulator of APOE-associated disease risk
One potential mediator of heightened risk for AD in women is the loss of circulating
estrogens coincident with the onset of the menopausal transition. Multiple studies
implicate the precipitous loss of 17-β estradiol (E2), the most prevalent circulating
estrogen, at menopause as a contributing factor for age and disease-associated cognitive
decline (Jacobs et al., 2016; Paganini-Hill & Henderson, 1996). In fact, female AD
patients have lower levels of endogenous E2 than age-matched controls (Manly et al.,
2000; Tsolaki et al., 2005). Just as low levels of circulating E2 are tied to cognitive decline,
treatment with exogenous E2 is often linked to better health outcomes. Studies including
female subjects taking estrogen replacement therapy, although somewhat controversial,
offer support for the idea that E2 may be beneficial for AD patients depending on timing
of initiation and treatment regimen (Henderson, 2006). For example, risk for developing
AD was reduced in individuals undergoing estrogen replacement therapy, an effect that
was magnified when dosage and length of treatment increased (Paganini-Hill &
Henderson, 1996).
Importantly, female APOE4 carriers seem less receptive to the beneficial effects
of E2 relative to APOE4-negative counterparts (Yaffe et al., 2000). Clinical work is
consistent with evidence from basic research; APOE2 and APOE3, but not APOE4, acted
synergistically with E2 to promote neurite outgrowth in mixed cell cultures, suggesting that
APOE4 expression renders cells uniquely nonresponsive to E2 (Nathan et al., 2004).
Combined, the above results suggest that E2 may be beneficial for carriers of APOE3
alleles, and unhelpful or even deleterious for APOE4 carriers.
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17β-estradiol in learning and memory
In normal, nonpathological states, E2 can facilitate cognitive processes. In healthy
adult mice, treatment with exogenous E2 facilitates memory via rapid activation of cell
signaling within the dorsal hippocampus (DH), thereby increasing protein expression of
phosphorylated

proteins

such

as

extracellular

signal-regulated

kinase

and

phosphatidylinositol 3-kinase, eukaryotic initiation factor 4E binding protein , cAMPresponse element binding protein, and other memory-related molecules (Boulware et al.,
2013; Fernandez et al., 2008; Fortress, Fan, et al., 2013; Tuscher, Luine, et al., 2016).
These cell-signaling events driven by E2 treatment are accompanied by an increase in
dendritic spine density in the DH and in the medial prefrontal cortex (Tuscher, Luine, et
al., 2016). However, whether a similar treatment regimen of E2 can facilitate memory,
activate cell-signaling cascades, and increase dendritic spine density in a model of AD is
unknown. Furthermore, whether exogenous E2 may interact with APOE in a genotypespecific manner to modulate memory and its associated neural correlates remains an
open question.

The EFAD model
Despite evidence implicating the interaction between APOE genotype and sex as a
crucial determinant of AD risk, the intersection of genotype and sex is frequently
overlooked. Transgenic (Tg) mice are an important tool to leverage towards establishing
the basic neurobiological underpinnings of factors, such as genotype and sex, associated
with increased AD risk. EFAD-Tg mice express 5 familial AD mutations (5xFAD) that
11

contribute to accumulation of Aβ42, and express human APOE3 (E3FAD) or APOE4
(E4FAD), making them ideal subjects for investigating the relative contributions of APOE
genotype and sex (Tai et al., 2017; Youmans et al., 2012). Targeted replacement of
murine APOE with human APOE is a key feature of this model (Youmans et al., 2012),
given significant structural and functional differences between the two (Fagan et al.,
2002). The EFAD model recapitulates human clinical presentation of APOE-associated
AD, such that female mice homozygous for APOE4 (E4FAD) exhibit earlier onset of, and
more advanced, disease pathology relative to other groups (Stephen et al., 2019; Thomas
et al., 2016). E4FAD females also have the shortest lifespan among the EFAD allelic
variants, followed by E4FAD males and E3FAD females, and finally by E3FAD males
(Balu et al., 2019). Given the aforementioned data suggesting that the EFAD model
appropriately stratifies sex and genotype differences, the EFAD mouse model is uniquely
suited for investigation of genotype and sex differences in concert.

Summary and significance
Female sex and APOE genotype act synergistically to increase AD risk and
severity, an effect that can be modeled with EFAD mice (Tai et al., 2017; Youmans et al.,
2012). Furthermore, although infusion of E2 into the dorsal hippocampus of young adult
mice can enhance object memory via cell signaling activation and increases in dendritic
spine density, whether intrahippocampal E2 is of mnemonic benefit in mice with AD-like
pathology remains unclear. Therefore, the overall objective of the dissertation was to
elucidate the interactions among sex, APOE genotype, and E2 in a mouse model of AD
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meant to recapitulate APOE-associated disease risk, and their relative influence on
memory and anxiety-like behaviors, protein expression, and dendritic spine density. In
the first experiment of this dissertation, we tested whether APOE4 genotype and female
sex interacted to adversely affect memory consolidation and anxiety-like behavior in the
EFAD model. We also asked whether APOE4 genotype and female sex interacted to
negatively influence protein expression in the DH, and dendritic spine density and
morphology in the DH and mPFC. The methods, results, and implications of this
experiment are discussed in Chapter 2. In the second experiment of this dissertation, we
tested whether APOE4 genotype and gonadal status modulate anxiety-like behavior in
the open field in female EFADs. Chapter 3 covers methods, results, and discussion of
this second experiment. Lastly, in the third experiment of this dissertation, we tested
whether APOE4 genotype prevented the memory-enhancing effects of E2. This final
experiment comprises Chapter 4 of the dissertation. Our long-term goal is to identify
molecular mechanisms that underly APOE4-associated cognitive dysfunction, and that
may be differentially and concurrently affected by sex and E2. Chapter 5 summarizes the
broad implications of the results from the dissertation and suggests future directions.
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CHAPTER TWO: Defining the impact of APOE genotype on sex differences in
memory formation and neural function in EFAD mice
The primary objective of this experiment was to determine whether APOE
genotype and sex act independently or together to modulate object memory
consolidation, protein expression, and dendritic spine density and morphology. Although
APOE4 genotype and female sex contribute to AD risk both independently and together
(Altmann et al., 2014; Bretsky et al., 1999; Farrer et al., 1997), the factors underlying the
relationship between these two variables are poorly understood.
In existing rodent models of AD, disease severity is disproportionately exacerbated
in females relative to males, as reflected by worsened neuropathological and cognitive
outcomes (Schmid et al., 2019; Wang et al., 2003; Yue et al., 2011). Likewise, in rodent
models designed to interrogate the impact of APOE status on cognitive function and
neural correlates of AD, either through knockout of APOE or targeted replacement of
murine APOE with human APOE, APOE4 has a deleterious effect on cognitive capacity,
dendritic spine density, neurogenesis, and synaptic integrity (Ji et al., 2003; Koutseff et
al., 2014; Wang et al., 2005). However, APOE genotype and sex are rarely accounted for
in concert in studies using animal models of AD to investigate molecular and behavioral
disease correlates. Thus, the EFAD model is uniquely suited for interrogating the ways in
which female sex and APOE4 genotype interact against a background of AD-like
pathology. Because cell signaling dysregulation and neuroanatomical changes have
been implicated in the pathogenesis of AD (Herms & Dorostkar, 2016; Pei et al., 2002),
asking how female sex and APOE4 genotype modulate protein expression and dendritic
spine density could provide novel insight into mechanisms contributing to individual
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differences in disease severity. Our working hypothesis was that female APOE4expressing EFAD mice would exhibit impaired memory consolidation, protein expression,
and decreased dendritic spine density and morphology relative to other groups.

Materials and Methods
Subjects
Male and female EFAD (APOE+/+/5xFAD+/-) mice co-express five familial AD mutations
(APP K670N/M671L + I716V + V717I and PS1 M146L + L286V) under control of the
neuron-specific mouse Thy-1 promoter, and are homozygous for human APOE3 or
APOE4 (Youmans et al., 2012). EFAD mice were bred, weaned, and genotyped at the
University of Illinois Chicago (UIC; Animal use protocol 17-066) before shipment to the
University of Wisconsin-Milwaukee (UWM) at 2 months (M) of age, where they were aged
to 6M before the start of behavioral testing (animal use protocol 19-20-03). At both UIC
and UWM mice were housed in groups of up to 5 per cage and maintained on a 12 hours
(h) light/dark cycle with ad libitum access to food and water. Mice were received from UIC
and behaviorally tested in two separate cohorts, whereas brain analyses for all mice were
conducted at the same time. Procedures followed the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were approved by the UIC Animal Care
Committee and UWM Institutional Animal Care and Use Committee.
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General Experimental Design
At 6M, male and female mice were tested in a battery of commonly used hippocampusdependent memory tasks including object recognition (OR), object placement (OP), and
the Morris Water Maze (MWM) (Fig. 1). The order of OR and OP testing was counterbalanced across groups such that half of the mice underwent OR first, whereas the other
half underwent OP first to eliminate any order-of-testing effects. Mice were then tested in
the MWM. Two weeks after the completion of all behavioral testing, brains were extracted
and hemisected for Golgi analysis and Western blotting experiments. The dorsal
hippocampus was immediately dissected from the whole brain or from the left hemisphere
and frozen at -80°C for Western blotting (n= 9-16/group), and right hemispheres were
collected for Golgi staining and morphological analysis (n = 5-7/group). These sample
sizes are sufficiently powered to detect between group differences.

Fig. 1. Experimental timeline. Mice were bred at the University of Illinois Chicago (UIC)
and were then sent to the University of Wisconsin-Milwaukee (UWM) at 8 weeks of age,
where they were aged for four months prior to the start of testing. At 6 months of age,
mice were tested in the object recognition and object placement tasks, followed by Morris
water maze testing. At 7 months of age, brain tissue was collected and analyzed.
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Behavioral testing
Object Recognition (OR) and Object Placement (OP)
To determine whether sex differentially or synergistically with APOE3 or APOE4
genotype influences memory for a previously seen object or location, object recognition
and spatial memory were tested in male and female E3FAD and E4FAD mice (n = 1216/group) using the OR and OP tasks, as described previously (Boulware et al., 2013;
Fernandez et al., 2008; Fortress, Schram, et al., 2013; Kim et al., 2016; Koss et al., 2018;
Taxier et al., 2019; Tuscher, Szinte, et al., 2016). Briefly, mice were handled for 30
seconds (s)/day for 3 days and then habituated to the testing arena for 5 minutes (m)/day
for 2 consecutive days. On the training day, mice were returned to the empty arena for
2m, and then were removed to a holding cage, during which time 2 identical objects were
placed 5cm from the upper left and right corners of the arena. Upon their return to the
arena, mice freely interacted with the objects until they accumulated 30s of object
exploration (or until 20m elapsed). Mice were then returned to their home cage for 24h or
4h to await testing in OR and OP, respectively; wild-type mice exhibit intact memory for
the identity (OR) and location (OP) of objects at these timepoints (Boulware et al., 2013;
Fortress, Schram, et al., 2013; Kim et al., 2016).
During OR testing, one familiar training object was replaced with a novel object. Mice
again freely interacted with the objects until they accumulated 30s of object exploration.
Mice that remember the familiar training object spend more time than chance (15s) with
the novel object during testing. During OP testing, one training object was moved to a
new location (bottom left or right corner). Mice that remember the location of the training
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objects spend more time than chance (15s) with the moved object during testing. Time
spent with the objects and time to accumulate 30s were recorded using ANYmaze
automated tracking software (San Diego Instruments).
Morris Water Maze
Spatial memory was also tested using the MWM, as described previously (Benoit et
al., 2015; Harburger et al., 2007). Data were recorded using ANYmaze software. A 4-trial
shaping procedure was conducted one day prior to testing to acclimate the mice to
escaping onto a 10x10 cm platform. Spatial memory was then tested in 5 consecutive
daily sessions consisting of 6 trials/day. The first 5 trials were hidden platform trials during
which the escape platform was located 1.5 cm below the water’s surface. Mice were
allowed 60s to find the platform. The sixth trial was a 60s probe trial in which memory was
tested in the absence of the platform, which was lowered for the first 30s, then raised and
available for escape for the remainder of the trial to discourage extinction of escape
behavior. The platform remained in the same place throughout testing and the intertrial
interval was 10-20m. During hidden platform trials, swim time (s), swim distance to
platform location during the first trial (cm), and swim speed (cm/s) were recorded using
ANYmaze. Swim distance to platform location during the first trial (cm) was also recorded
as a measure of retention of learning from the previous day’s acquisition trials. During
probe trials, the % time in the correct quadrant (containing the platform), time to first entry
into the correct quadrant (s), average distance from the platform (cm), and # of platform
crossings during the first 30s of the probe trial were measured.
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One day after spatial testing, mice were tested in a cued version of the task in which
the escape platform was raised above the surface of the water and made visible with red
tape. Because memory is not necessary to locate the platform, this task assesses
motivation, visual ability, and swimming ability. Six trials/day were conducted for 3
consecutive days during which the platform location changed for each trial. Swim time,
swim distance, and swim speed were recorded.

Western blotting
Western blotting was used to determine the extent to which sex and APOE genotype
alter the expression of several categories of proteins in the dorsal hippocampus 5m after
training with novel objects. This brain region is of particular interest due to abundant
evidence that integrity of hippocampal function is compromised in AD, and previous work
using the EFAD model suggesting that sex and APOE genotype may modulate protein
expression within this brain region (Liu et al., 2015).
Western blotting was conducted as described previously (Boulware et al., 2013;
Fernandez et al., 2008; Fortress, Schram, et al., 2013; Kim et al., 2016; Koss et al., 2018;
Taxier et al., 2019; Zhao et al., 2012). Tissue samples were suspended 1:25 w/v in
hypotonic lysis buffer and homogenized. Homogenates were electrophoresed on 10%
TGX (Tris-Glycine eXtended) stain-free precast gels (Bio-Rad) and transferred to
polyvinylidene fluoride membranes; protein transfer was verified using a ChemiDoc MP
gel imager (Bio-Rad). After blocking in 5-8% milk, membranes were incubated overnight
at 4°C in primary antibodies. The following day, blots were incubated at room temperature
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with the appropriate secondary antibody. Blots were developed using Clarity Max
chemiluminescent substrate (Bio-Rad) and protein expression detected using a
ChemiDoc MP gel imager. Densitometry was performed using Image Lab software (BioRad Image Lab v 5.2). Phosphorylated proteins were normalized to their respective total
proteins. The remaining blots were stripped and reprobed for β-Actin (#4967, 1:1000, Cell
Signaling Technology) for protein normalization. Data were expressed as average volume
intensity as a percentage compared to male E3FADs.

Golgi Impregnation and Analyses
Left hemispheres (n=5-7/group) were collected for Golgi impregnation, which was
performed as described previously (Frankfurt et al., 2011; Kim et al., 2019; Tuscher,
Luine, et al., 2016) using the Rapid Golgi Stain Kit (FD Neuro Technologies). Tissue was
sliced into 100μm sections and mounted on gelatin-coated microscope slides, which were
coded so that the individual counting spines was blind to treatment.
Secondary basal dendrites and tertiary apical dendrites were counted from pyramidal
neurons in the dorsal hippocampal CA1 and layer II/III of the mPFC under an Olympus
BX51WI microscope (100x with oil) using NeuroLucida (v 11.08, MBF Bioscience).
Selected dendrites were between 10-20μm in length and 0.5-1.3μm thick. Neurons
selected for analysis were required to have well impregnated cell bodies and dendrites,
and had to be clearly distinguishable from adjacent cells. Two dendritic segments/neuron
and 6 cells/region were included in the analysis. Spine density was calculated as the
number of spines/10μm dendrite.
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Dendritic spines were identified according to three categories based on shape:
mushroom, stubby, or thin (Harris et al., 1992; Kim et al., 2019). Mushroom spines had
head diameters at least twice the size of their neck diameters, whereas stubby spines
had neck diameters relatively equal to the total length of the spine. Thin spines had head
diameters less than or equal to their neck diameters.
CA1 dendritic complexity was quantified in using Sholl analysis under an Olympus
BX51WI microscope (100x with oil). Cell bodies, apical dendrites, and basal dendrites
were traced using NeuroLucida (v 11.08, MBF Bioscience). Neurons selected for tracing
had to be present within the middle thickness of the section, be fully impregnated, and
have at least 3 primary basilar dendrites, each of which needed to branch at least once.
Concentric spheres were used to count the number of intersections made by dendritic
branches at successive 10μm steps from the cell body. The number of intersections made
by dendritic branches at increasing diameters from the soma served as a measure of
dendritic complexity (Sholl, 1953). Sholl analysis was attempted in the mPFC but was not
completed because Golgi stain penetrance was not as robust as in CA1, and therefore
was not reflective of full branching complexity.

Statistical Analyses
Statistical analyses were performed using GraphPad Prism 9. For OR and OP, onesample t tests were used to determine whether the time spent with each object differed
from chance (15s), which assesses within-group learning. Between-group differences
were assessed using two-way ANOVAs with sex and genotype as between-subject
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variables. Similar two-way ANOVAs were used to analyze Western blot and dendritic
spine density data. For the MWM, two-way repeated measures ANOVAs, with sex and
genotype as between subject variables, and session as the repeated measure, were
conducted to evaluate within and between-group differences in learning across days. For
Sholl analysis, two-way repeated measures ANOVAs, with sex and genotype as between
subject variables and distance from the cell soma as the repeated measure, were
conducted to evaluate within and between-group differences in dendritic complexity.
Significant main effects were followed by planned comparisons where appropriate, given
our a priori hypothesis that deficits would be greatest in female E4FAD mice, followed by
E4FAD males, E3FAD females, and then E3FAD males. Statistical significance was set
at p < 0.05 for all statistical tests, and trends were determined by p < 0.10.

Results
Object Recognition
Male E3FADs spent significantly more time than chance (15s) with the novel object
during testing (Fig. 2A; t(15) = 5.35, p < 0.0001; n=12-16/group), indicating intact memory
for the identity of the training objects. By contrast, female E3FADs and E4FADs of both
sexes did not spend significantly more time than chance with the novel object during
testing, suggesting impaired object recognition memory among all but the male E3FAD
group. E3FADs spent more time with the novel object during testing than E4FADs (F(1, 55)
= 5.82 , p = 0.02), an effect driven by male E3FADs, which spent more time with the novel
object than E4FADs of both sexes (p = 0.01). No other main effects or interactions were
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significant. Time to accumulate 30s of object exploration did not differ among male
E3FADs (M = 461.68, SEM = 51.0), female E3FADs (M = 443.89, SEM = 49.44), male
E4FADs (M = 508.63, SEM = 73.06), or female E4FADs (M = 545.76, SEM = 74.39),
suggesting that total activity or motivation to explore objects was not impacted by sex or
APOE genotype.

Fig. 2. All mice but male E3FADs displayed impaired object recognition and spatial
memory formation. Only male E3FADs exhibited intact memory for the identity (A) and
location (B) of the training objects. Male E3FADs spent significantly more time than
chance (dashed line at 15 sec; ^p < 0.05) with the novel (A) and moved (B) objects during
testing. E3FADs spent more time than E4FADs with the novel object (&p < 0.05 = main
effect of genotype), and male E3FADs spent significantly more time than E4FADs of
either sex with the novel object (**p < 0.01). Bars represent mean ± standard error of the
mean (SEM).

Object Placement
Similar results were observed for OP. Male E3FADs spent significantly more time than
chance with the moved object during testing (Fig. 2B; t(15) = 3.360, p = 0.0043; n=12-
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16/group), suggesting intact memory for the location of the training objects. As in OR,
female E3FADs and E4FADs of both sexes did not spend more time than chance with
the moved object during testing. Neither the main effects nor interaction were significant
for OP. Again, time to accumulate 30s of object exploration did not differ among male
E3FADs (M = 407.66, SEM = 33.53), female E3FADs (M = 363.61, SEM = 37.63), male
E4FADs (M = 436.12, SEM = 31.24), or female E4FADs (M = 426.46, SEM = 53.6).
Together, within-subjects t-tests for OR and OP indicate that only male E3FADs
exhibited intact memory for previously learned objects or locations, and suggest both a
detrimental effect of APOE4 genotype on object recognition and spatial memory, as well
as an interesting sex difference favoring males within the APOE3 genotype.
Morris Water Maze
All ANOVA statistics for each MWM measure are presented in Table 1 (n=14-16/group
for all measures). The sections below summarize the main effects and interactions, and
present results of planned comparisons where appropriate.
Two male E4FADs and two female E4FADs were excluded from all water maze
analyses because their average swim speed was greater than two standard deviations
away from their respective group’s average swim speed in visible platform trials. All four
excluded mice also spent time immobile (i.e., floating) during the task, suggesting that
they were not motivated to search for the hidden platform.

24

Table 1. ANOVA statistics for Morris Water Maze variables
Variable

Sex

Genotype

Spatial

Swim time

F(1,54)=0.53

Swim distance

F(1,54)=0.24

F(1,54)=22.42,
p<0.0001
F(1,54)=0.42

Swim
distance, 1st
trial
Swim speed

F(1,54)=2.36

F(1,54)=3.62,
p=0.63

F(1,54)=0.79

F(1,54)=34.72,
p<0.0001
F(1,53)=0.0007

F(1,54)=0.017

Quadrant time

F(1,54)=4.38,
p=0.04
F(1,53)=2.78

Avg distance

F(1,54)=1.42

F(1,54)=0.33

Time to 1st
entry
Platform
crossings

F(1,54)=0.58

F(1,54)=2.26

F(1,54)=0.29

F(1,54)=1.98

Swim time

F(1,54)=0.003

F(1,54)=0.78

Swim distance

F(1,53)=6.408e005
F(1,54)=0.52

F(1,53)=0.03

F(1,54)=3.56,
p<0.065
F(1,53)=1.96

F(1,54)=0.68

F(1,54)=0.27
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Task

Cued

Swim speed

Sex x
Genotype
F(1,54)=0.08
F(1,54)=0.20

F(1,53)=4.16,
p=0.046
F(1,54)=2.85,
p=0.1
F(1,54)=4.7,
p=0.03
F(1,54)=5.46,
p<0.02

Session

Session x Sex

F(3.48,187.9)=23.51,
p<0.0001
F(3.19,172.2)=61.3,
p<0.0001
F(2.88,155.7)=31.57,
p<0.0001

F(4,216)=1.39

Session x
Genotype
F(4,216)=0.23

Session x Sex
x Genotype
F(4,216)=2.71,
p<0.03
F(4,216)=1.78

F(4,216)=1.25

F(4,216)=0.09

F(4,216)=1.38

F(4,216)=2.36,
p=0.05

F(4,216)=1.64

F(3.21,173.1)=21.54,
p<0.0001
F(3.46,183.2)=23.64,
p<0.0001
F(3.36,181.2)=36.22,
p<0.0001
F(3.643,196.7)=4.07,
p<0.046
F(3.74,
201.9)=4.089,
p<0.005

F(4,216)=0.7

F(4,216)=2.01

F(4,216)=0.47

F(4,212)=2.05

F(4,212)=1.25

F(4,216)=2.4,
p=0.05
F(4,216)=1.19

F(4,212)=3.48,
p<0.009
F(4,216)=3.1,
p<0.02
F(4,216)=0.45

F(4,216)=0.25

F(4,216)=0.42

F(4,216)=0.89

F(1.69,90.96)=56.98,
p<0.0001
F(1.65,87.54)=6.01,
p<0.006
F(1.46,78.90)=19.97,
p<0.0001

F(2,108)=0.15

F(2,108)=0.36

F(2,108)=0.23

F(2,106)=0.06

F(2,106)=0.69

F(2,106)=0.46

F(2,108)=3.45,
p<0.04

F(2,108)=0.95

F(2,108)=0.06

F(4,216)=1.47
F(4,216)=1.12

Spatial learning trials
Mice of both genotypes could learn the location of the hidden platform, as indicated
by significant main effects of session (Table 1) for swim time (Fig. 3A), cumulative swim
distance (Fig. 3B), and swim speed (Fig. 3C). The main effect of genotype was significant
for swim time and swim speed, such that E3FADs swam faster and located the platform
in less time than E4FADs. The main effect of genotype was not significant for swim
distance, suggesting that the genotype effect in swim time may be due primarily to
differences in swim speed. The main effect of sex was significant only for swim speed, in
which females swam faster than males.
Sex and genotype effects varied across sessions, as indicated by a significant session
x sex x genotype effect for swim time and session x genotype effect for swim distance in
the first trial. Indeed, by sessions 3 (halfway through testing) and 5 (end of testing),
E3FADs of both sexes reached the platform in less time than during session 1 (p < 0.05),
whereas E4FADs of both sexes did not (Fig. 3A), suggesting that E3FADs of both sexes
learned the platform location more rapidly than E4FADs. In addition, the swim times of
E3FAD males were significantly faster than E4FAD males in session 4 (p = 0.02). Male
E4FADs also had a significantly and unusually higher spatial swim times than other
groups during session 4, potentially driven by their slower swim speed.

Overall,

these data suggest minimal effects of sex or genotype on learning-related parameters
(e.g., spatial swim time or spatial swim distance) associated with Morris water maze task
acquisition.

26

Fig. 3. All groups learned the platform location in the hidden platform trials of the
Morris Water Maze. Spatial swim time (A), swim distance (B), and swim speed (C)
decreased across sessions in all groups. Differences between sessions within a group
are indicated with asterisks that match the group’s line/symbol color (*p < 0.05; dark blue
= male E3FAD, light blue = female E3FAD, red = male E4FAD, pink = female E4FAD).
Between-group differences are indicated above the session during which they occurred
(§ = male E3FAD vs male E4FAD; ¶ = female E3FAD vs male E4FAD). Symbols
represent the mean ± SEM.
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Probe trials
During the first 30s of each daily probe trial, the platform was submerged and
inaccessible for escape. As in the spatial learning trials, significant session effects for the
percent time spent in the target quadrant (quadrant time; Fig. 4A), average distance to
the platform (distance to platform; Fig. 4B), time taken to first enter the location of the
platform (time to first entry; Fig. 4C), and platform crossings (Fig. 4D) indicated that all
groups learned the location of the hidden platform. Effects of sex were limited to a single
sex x session interaction for distance to the platform and sex x genotype interactions
present in all measures but distance to the platform (although there was a weak trend of
p = 0.097). Effects of genotype also varied by session, as indicated by session x genotype
interactions for quadrant time and distance to the platform. Performance in all measures
tended to be quite variable, making definitive conclusions about effects of sex and
genotype difficult to draw. In general, male E3FADs tended to outperform other groups in
sessions 1-3, where they spent more time in the target quadrant, swam shorter distances
to the platform, entered the platform area faster, and made more platform crossings than
other groups. One notable between-group difference was observed in quadrant time,
where male E3FADs spent more time in the target quadrant than female E4FADs during
session 1 (Fig. 4A; p < 0.03). E3FAD males also tended to outperform E4FAD males in
sessions 1-3. Although subtle sex and genotype interactions were observed in withingroup performance, the overall variability and lack of main effects of sex or genotype on
probe trial measures suggests that neither sex nor genotype significantly modulated
memory expressed in the probe trials of this task.
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Fig. 4 Spatial memory in the probe trials of the Morris water maze was similar in all
groups. Percent time in target quadrant (A) and number of platform crossings (D)
increaesed across sessions. Distance to the platform (B) and latency to enter the
platform’s location (C) decreased across sessions. Differences between sessions within
a group are indicated with asterisks that match the group’s line/symbol color (* p < 0.05;
dark blue = male E3FAD, light blue = female E3FAD; red = male E4FAD, pink = female
E4FAD) One between-group difference is indicated above the session during which it
occurred (ǂ = male E3FAD vs female E4FAD). Symbols represent the mean ± SEM.
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Fig. 5 Performance
in the cued (visible
platform) trials of
the Morris water
maze did not differ
among
groups.
Swim time (A) and
swim distance (B)
decreased
across
sessions,
whereas
swim
speed
(C)
increased. Between
time point differences
within strains are
color matched (* p <
0.05; dark blue =
male E3FAD, light
blue
=
female
E3FAD; red = male
E4FAD,
pink
=
female
E4FAD).
Symbols represent
the mean ± SEM.

Cued trials
All groups learned
to find the visible platform, as indicated by main effects of session for cued swim time
(Fig. 5A), swim distance (Fig. 5B), and swim speed (Fig. 5C). No effects of genotype were
observed in any measure, and the sole sex effect was a sex x session interaction for swim
speed, reflecting faster speeds in male E4FADs in sessions 2 and 3 compared to session
1 (p < 0.001). These data suggest that EFAD mice of either sex or genotype can learn to
locate and swim to a visible platform, indicating no adverse effects of sex or genotype on
sensorimotor abilities, motivation, or swimming ability.
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Western Blotting
Synaptic proteins
E3FADs of both sexes exhibited higher levels of PSD95 (Fig. 6A; F(1, 50) = 6.24 , p =
0.02) and synaptophysin (Fig. 6B; F(1, 50) = 5.17, p = 0.03) than E4FADs of both sexes
(n=14/group). PSD95 levels were higher in E3FAD females than E4FAD females (p =
0.03). Combined, these data suggest a detrimental effect of APOE4 genotype on synaptic
proteins, perhaps indicating a reduction in synapse or dendritic spine density.
Glial proteins
Females had elevated GFAP relative to males (Fig. 6C; F(1, 50) = 10.01, p = 0.003;
n=13-14/group) and there was a trend for E4FADs to have elevated GFAP relative to
E3FADs (Fig. 6C; F(1, 50) = 3.8, p = 0.057). These effects were driven by elevated levels
of GFAP in female E4FADs compared to every other group (p = 0.004 vs male E3FAD; p
= 0.06 vs female E3FAD; and p = 0.008 vs male E4FAD) and suggest a potential increase
in dorsal hippocampal astrocytes or astrocytic activation among female E4FADs. In
contrast to GFAP, there were no effects of sex or genotype, nor interactions, in levels of
Iba1 (Table 2; n=13-14/group), indicating a lack of sex and APOE genotype effects on
microglial protein expression in the dorsal hippocampus.
Membrane-associated proteins
ERα interacts with mGluR1 at the cell membrane to increase phosphorylation of the
42-kDa isoform of ERK (p42 ERK) and cyclic-AMP response element binding protein
(pCREB; Boulware et al., 2005), and increased p42 ERK phosphorylation is necessary
for ERα activation to enhance memory in the OR and OP tasks (Boulware et al., 2013).
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Here, E3FADs exhibited lower ERα levels than E4FADs (Fig. 6D; F(1, 47) = 5.88, p = 0.02;
n=11-14/group), an effect driven by male E3FADs, whose ERα levels were lower than
E4FADs of both sexes (F(1,15) = 5.67,

p < 0.03; p = 0.03 vs male E4FAD; p = 0.04 vs

female E4FAD). No effects of sex or APOE genotype were observed for ERβ protein
expression (Table 2, n = 13-14/group), indicating that the effect of APOE genotype on
nuclear estrogen receptor protein expression was specific to ERα. In addition, caveolin-1
protein levels were not affected by sex or genotype (Table 2; n=11-16/group).
Cell-signaling proteins
Males expressed higher pCREB levels than females (Fig. 4E; F(1, 45) = 4.61, p = 0.04;
n=10-15/group). In contrast, no effects of sex or genotype, nor any interactions, were
observed for p42 ERK, pPI3K, p4EBP, pcofilin, p46 JNK, or p54 JNK (Table 2; n=915/group), suggesting that these phospho proteins are not upregulated in the dorsal
hippocampus of EFAD mice 5m after learning.
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Fig. 6. E4FAD mice, particularly E4FAD females, displayed altered levels of several
dorsal hippocampal proteins. (A) Representative blots illustrate relative group
differences in protein expression. (B,C) Synaptic proteins PSD95 and synaptophysin
were decreased in E4FADs relative to E3FADs (&p < 0.05). (D) GFAP protein expression
was increased in female EFADs relative to male EFADs ($p < 0.05, main effect of sex)
and tended to be higher in E4FADs than in E3FADs (&p = 0.057). (E) ERα levels were
significantly higher in E4FADs than in E3FADs (&p < 0.05). (F) Levels of pCREB were
significantly higher in male EFADs relative to female EFADs ($p < 0.05). *p < 0.05 =
between-group differences, &p < 0.05 = main effect of genotype, $p < 0.05 = main effect
of sex. Bars represent the mean ± SEM.
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Table 2. Proteins in dorsal hippocampus unaffected by sex or APOE genotype
Protein*

E3FAD

E4FAD
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Male

Female

Male

Female

Iba1

100.0 ± 7.52

93.84 ± 5.90

104.9 ± 7.67

113.4 ± 9.48

Caveolin-1

100.0 ± 5.09

100.6 ± 9.93

110.1 ± 9.39

108.3 ± 12.5

ERβ

100.0 ± 5.41

98.54 ± 5.72

102.4 ± 5.1

106.8 ± 4.35

p42 ERK

100.0 ± 7.48

115.85 ± 10.65

94.31 ± 5.68

98.29 ± 9.13

pPI3K

100.0 ± 7.78

98.78 ± 5.44

91.82 ± 6.13

97.14 ± 8.47

p4EBP

100.0 ± 8.35

130.38 ± 12.25

110.15 ± 11.3

108.37 ± 13.86

pcofilin

100.0 ± 9.67

106.5 ± 16.1

114.5 ± 12.5

109.9 ± 9.86

p46 JNK

100.0 ± 2.97

101.2 ± 3.09

99.06 ± 3.15

104.2 ± 3.25

p54 JNK

100.0 ± 4.12

108.7 ± 3.85

99.93 ± 5.17

103.0 ± 3.88

*All proteins normalized to the male E3FAD group, whose values were set to 100.
Values represent mean % immunoreactivity (± SEM) for the target protein divided by b-actin (Iba-1, Caveolin-1, ERβ) or
unphosphorylated total protein (all phospho proteins).

Dendritic analyses
We next examined apical and basal dendritic spine density in hippocampal area CA1
and in the prelimbic/infralimbic area of the mPFC to assess whether sex and APOE
genotype influence dendritic spine anatomy. Neither sex nor genotype affected the
density of apical spines in CA1 or mPFC (Table 3). Sex also did not affect basal spines
in either brain region. Effects of genotype on basal spines are detailed below.
CA1
Total CA1 basal spines varied significantly by genotype (F(1, 23) = 8.75, p = 0.007; n=67/group), such that E4FADs had reduced total basal spine density compared to E3FADs
(Fig. 7A, B). Differences in total basal spine density were driven by alterations in
mushroom spines (Fig. 7C; F(1, 23) = 3.96, p = 0.059) and stubby spines (Fig. 7D; F(1, 23) =
8.75, p = 0.007). In both cases, E4FADs exhibited lower density than E3FADs. Stubby
spine density was lower in male E4FADs than in female E3FADs (p = 0.05). Neither sex
nor genotype affected CA1 basal thin spine density (Table 3). Combined, these data
indicate that APOE4 genotype contributes to a selective reduction in basilar spine density
in the dorsal hippocampus relative to APOE3 genotype. That mushroom and stubby
spines were specifically affected suggests that E3FADs have more mature and
intermediate spines on basilar dendrites relative to E4FADs.
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Table 3. CA1 and mPFC basal thin and apical spine density measures unaffected by sex and genotype

Brain region
CA1

mPFC

Spine type

E3FAD

E4FAD

36

Male

Female

Male

Female

Basal thin

3.55 ± 0.28

3.59 ± 0.33

3.70 ± 0.28

3.67 ± 0.13

Apical total

15.5 ± 0.61

15.7 ± 1.11

15.7 ± 0.50

15.6 ± 0.38

Apical mushroom

3.70 ± 0.40

3.37 ± 0.34

3.79 ± 0.34

3.64 ± 0.19

Apical stubby

5.80 ± 0.50

5.71 ± 0.31

5.86 ± 0.56

5.95 ± 0.36

Apical thin

5.89 ± 0.34

6.35 ± 0.53

5.91 ± 0.34

5.77 ± 0.30

Basal thin

2.14 ± 0.11

2.54 ± 0.23

2.42 ± 0.22

2.50 ± 0.41

Apical total

9.22 ± 0.31

9.07 ± 0.22

8.77 ± 0.30

8.67 ± 0.35

Apical mushroom

3.24 ± 0.18

3.23 ± 0.34

2.99 ± 0.41

2.95 ± 0.34

Apical stubby

2.95 ± 0.36

2.65 ± 0.19

2.51 ± 0.18

2.41 ± 0.17

Apical thin

2.92 ± 0.17

3.15 ± 0.32

3.29 ± 0.33

3.30 ± 0.33

Values represent mean spines/10 µM ± SEM.

Fig. 7. E4FADs of both sexes exhibited reduced CA1 dendritic spine density. (A)
Representative images at 100x of basilar dendritic segments in CA1 illustrate relative
differences in spine density. (B) E4FADs exhibited lower total CA1 basal spine density
relative to E3FADs (&p < 0.05, main effect of genotype). In particular, E4FADs exhibited
reduced numbers of mushroom (C; &p = 0.059) and stubby (D; &p < 0.05) spines relative
to E3FADs. Bars represent the mean ± SEM.

Sholl analysis was used to evaluate whether sex acts independently or concordantly
with APOE3 or APOE4 genotypes to alter dendritic branching complexity within the CA1.
Dendritic intersections with concentric spheres placed at successive 10 μm intervals from
the cell soma were quantified. The pattern of dendritic branching was similar for all
groups; dendritic intersections increased in all groups until a distance of approximately
100 μm (apical) or 60 μm (basal) and then declined (Fig. 8). Although the main effect of
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distance from the soma was significant for both apical (F(37,851) = 240.0, p < 0.0001) and
basal (F(2.492, 57.31) = 350.8, p < 0.0001) dendritic intersections, sex and APOE genotype
did not influence morphological complexity of dorsal hippocampal CA1 pyramidal
neurons.

Fig. 8. Sholl analysis of CA1 dendritic branching complexity yielded no differences
among the groups. (A) Representative tracings of pyramidal cells from EFAD mice. (B)
No group differences in branching complexity were observed in either basal (A) or apical
(C) dendrites. Mean number of intersections ± SEM are plotted.
mPFC
The effects of genotype on dendritic spine density in the mPFC were identical to those
observed in CA1 (n=5-7/group). E4FADs exhibited reduced total mPFC basilar spine
density compared to E3FADs (Fig. 9A,B; F(1, 22) = 31.92, p < 0.0001). Total basal spine
density was higher
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in male and female E3FADs than in E4FADs of both sexes (p = 0.0008-0.01). As with
basilar CA1 spines, the genotype effect in total mPFC basal spine density was driven by
decreased mushroom (Fig. 9C; F(1, 22) = 15.02, p = 0.0008) and stubby (Fig. 9D; F(1, 22) =
5.12, p = 0.03) spine density in E4FADs relative to E3FADs. Relative to E4FADs of both
sexes, basal mushroom spine density was higher in male and female E3FADs (p = 0.0350.04).

Fig. 9 E4FADs of both sexes exhibited reduced mPFC dendritic spine density. (A)
Representative images at 100x of basilar dendritic segments in mPFC illustrate relative
differences in spine density. (B) E4FADs exhibited lower total mPFC basal spine density
relative to E3FADs (&p < 0.05, main effect of genotype). Notably, E4FADs exhibited
reduced numbers of mushroom (C) and stubby (D) spines relative to E3FADs (&p < 0.05).
Bars represent the mean ± SEM.
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Discussion
The neural mechanisms underlying the increased risk of AD to women APOE4
carriers are unclear, thus necessitating a better understanding of how sex and different
APOE genotypes influence cognition and brain function. Here, we used an EFAD mouse
model of AD to examine whether sex modulated differences between APOE3 and APOE4
genotypes in mnemonic function, protein expression, and dendritic morphology against
the backdrop of AD-like pathology previously reported in this model (Tai et al., 2017;
Youmans et al., 2012). We hypothesized that E4FAD mice (APOE4+/+/5xFAD+/-) would
exhibit impaired memory, reduced hippocampal levels of synaptic, membrane, and cellsignaling proteins, increased hippocampal levels of glial proteins, and decreased dendritic
spine density and branch complexity in CA1 and mPFC relative to 5xFAD mice
expressing two copies of human APOE3 (E3FAD). We further expected these changes
to be most pronounced in female E4FAD mice. The findings suggest that APOE4
genotype impaired spatial and object recognition memory consolidation in object-based
tasks, reduced hippocampal synaptic markers, and decreased dendritic spine density in
the CA1 and mPFC relative to APOE3, yet increased hippocampal levels of ERa (Fig. 7).
We observed surprisingly few sex differences or sex x genotype interactions in all
measured outcomes, suggesting that the known synergistic effects of APOE4 and female
sex are likely modulated by factors not measured in the present study.
Interestingly, sex differences in object-based memory were observed among
E3FADs, but not E4FADs. Specifically, only male E3FAD mice remembered the identity
and location of the training objects in the OR and OP tasks, suggesting impaired object
recognition and spatial memory consolidation not only in E4FADs of both sexes but also
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in E3FAD females. However, the sex differences in memory observed within E3FADs
were not reflected in any measure of neuronal structure or function, so the underlying
mechanisms remain unclear. This preserved brain function in E3FAD females may have
allowed them to find the platform in the MWM as well as E3FAD males, as E3FADs of
both sexes improved similarly across sessions in this task. Curiously, E3FADs of both
sexes had lower dorsal hippocampal Erα expression than E4FADs, suggesting either a
potential role for high ERα levels in APOE4-induced memory impairments, or a decrease
in ERα in E3FADs that serves to maintain memory. Levels of synaptic proteins and the
density of mature and developing basal dendritic spines in the CA1 and mPFC were
reduced in E4FAD mice of both sexes relative to male and female E3FAD mice,
suggesting a detrimental effect of APOE4 genotype, but not sex, on spine synapses and
synaptic plasticity. However, sex did affect levels of the astrocytic protein GFAP and the
transcription factor pCREB, with females expressing more GFAP and less pCREB.
Interestingly, female E4FADs expressed substantially higher levels of GFAP than E4FAD
males. These findings suggest increased astrogliosis in E4FAD females. Together, the
results indicate limited effects of sex on memory in EFAD mice, with no sex differences
observed among E4FADs in either task, and a sex difference (favoring males) only
evident among E3FADs in the two object tasks. These sex differences were not reflected
in any neurobiological measure, although sex differences unrelated to memory were
observed in GFAP and pCREB among E4FAD mice.
In previous work with C57BL/6 mice, ovariectomized females and gonadally-intact
or castrated males show intact memory in the OR and OP tasks when tested 24 or 4 h
later, respectively (Fortress et al., 2013; Kim et al., 2019; Koss et al., 2018; Taxier et al.,
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2019). Thus, these are delays at which wild-type mice can remember the identities and
locations of the training objects. Here, only male E3FAD mice exhibited intact memory in
both tasks. The superior object memory of E3FAD males compared to E4FADs of both
sexes is consistent with previous reports of reduced pathology in E3FAD males relative
to other EFADs (Youmans et al., 2012) and literature suggesting that APOE3 is less
detrimental to memory than APOE4 in both animal models and human AD patients
(Beydoun et al., 2012; Liu et al., 2015). In support, the impaired memory exhibited by
male and female E4FADs, as well as female E3FADs, is consistent with previous work
showing spatial and object memory impairments in rodent models of AD (Ardiles et al.,
2012; Ashe, 2001). Moreover, other AD mouse model studies report exacerbated memory
impairment in females relative to males (Schmid et al., 2019; Yang et al., 2018; Yue et
al., 2011). Thus, our data showing that female EFADs of both genotypes could not
remember the identity and location of previously seen objects are consistent with these
findings. Although we expected that all groups but female E4FADs would display intact
memory, AD pathology may have been sufficient by 6M to impair memory in male and
female E4FADs and in female E3FADs. E4FAD mice exhibit significant AD pathology and
behavioral deficits as early as 4M, especially relative to E2FAD mice (Liu et al., 2015), so
had we tested the mice at an earlier age, we may have captured sex differences in
memory within the E4FADs.
In contrast to the object tasks, all mice could learn to find the platform in the MWM
task. This is somewhat surprising, as swimming through a large water tank to find a
hidden platform seems inherently more complex than exploring objects in an open field.
Nevertheless, the lack of impairment among E4FADs is consistent with a previous
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comparison of 6 month-old female E3FAD and E4FAD mice showing minimal MWM
deficits in E4FADs relative to E3FADs (Liu et al., 2015). MWM training is much more
extensive than the object tasks and the number and length of training trials per day, in
addition to the robustness of room cues during water maze testing, may have greatly
aided spatial memory formation in the MWM among mice from all groups. A more
challenging training protocol (e.g., fewer trials or fewer cues) may have captured
between-group differences.
Because synaptic dysfunction is a key feature in AD (Masliah et al., 2006; Reddy
et al., 2005), we investigated whether sex and APOE genotype influence expression of
synaptic proteins within the dorsal hippocampus of EFAD mice. Our data showing a
reduction in PSD95 and synaptophysin levels in E4FADs relative to E3FADs, particularly
among females, is consistent with previous work showing reduced hippocampal PSD95
levels in 4 month-old female E4FAD mice relative to E3FAD females (Liu et al., 2015).
Our findings are also consistent with clinical data demonstrating that expression of
synaptophysin is markedly decreased in AD patients compared to healthy controls
(Heinonen et al., 1995), and in APOE4-expressing individuals relative to APOE3 carriers
(Love et al., 2006).
The lower levels of hippocampal synaptic proteins observed in E4FADs relative to
E3FADs are consistent with the reduced CA1 and mPFC basal dendritic spine density
also evident in E4FADs. Previous findings in APOE-TR mice indicate a detrimental effect
of APOE4 on cortical, but not hippocampal, spine density across aging (Dumanis et al.,
2009), although others using this model have reported an adverse effect of APOE4 on
spine density in the hippocampus (Ji et al., 2003). The decreased mushroom spine
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density observed in E4FADs suggests that E3FADs have more mature spines than
E4FADs, which is consistent with the overall negative effect of APOE4 genotype on
memory processes. Our finding of more stubby spines in E3FADs than E4FADs may
reflect ongoing cytoskeletal reorganization in dendritic spines. Previous work in a different
mouse model of AD suggests that stubby spines may be more dynamic than other spine
types (Spires-Jones et al., 2007). Because spine remodeling is a continual process (Kasai
et al., 2010), and our own data present only a snapshot of this process at a single
timepoint, we speculate that elevated stubby spine density in E3FADs reflects greater
spine plasticity, motility, recycling, and/or remodeling relative to E4FADs.
Moreover, the negative impact of APOE4 genotype on basal, but not apical, spine
density, in the current study suggests the intriguing possibility that APOE4 genotype does
not uniformly modulate spine density, but rather influences distinct sites of synaptic input
within both the mPFC and the dorsal hippocampus. Given reports that basal dendrites in
mPFC receive input from thalamic projections, and that communication between the
dorsal hippocampus and mPFC may be facilitated via the nucleus reuniens of the
thalamus (Hoover & Vertes, 2007), future work should interrogate whether changes in
basal dendritic spine density reflect compromised neurocircuitry between the dorsal
hippocampus and mPFC in EFAD mice.
In addition to neuronal morphology, we examined expression of glial proteins
because both astrocytic and microglial reactivity is closely linked to AD pathology (Meda
et al., 2001). Although neither sex nor APOE genotype affected microglial Iba-1
expression in the dorsal hippocampus, astrocytic protein GFAP was elevated in female
EFADs relative to male EFADs, and in E4FADs relative to E3FADs. Previous work
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showed striking differences in astrocytic reactivity between male E4FAD and E3FADs
(Tai et al., 2017), with E4FADs having elevated GFAP expression relative to E3FADs.
The present genotype effect differs in that it is primarily driven by elevated GFAP in female
E4FADs. The sex-specific effect on levels of GFAP, as well as the particularly high GFAP
levels in female E4FADs, suggests that both female sex and APOE4 genotype interact to
increase susceptibility to astrogliosis.
In our examination of cell-signaling proteins that are rapidly activated in response
to learning, we found that dorsal hippocampal pCREB levels were increased in male
EFADs relative to female EFADs. In the hippocampus of AD patients, CREB-mediated
transcriptional outcomes are dysregulated (Satoh et al., 2009), and pCREB is reduced
relative to age-matched controls (Yamamoto-Sasaki et al., 1999), suggesting that
aberrant hippocampal CREB signaling is a feature of AD. Although sex differences in
CREB-associated signaling remain poorly characterized in rodent models of normal or
pathological aging, previous work with CREB-deficient aging mice showed that aberrant
CREB signaling resulted in reduced spatial memory in females compared to males
(Hebda-Bauer et al., 2007). In addition, female 3xTg mice exhibited lower pCREB
expression relative to male 3xTg mice (Yang et al., 2018). These data are in line with our
own, suggesting that reduced pCREB is particularly exacerbated in female E4FADs
relative to male E4FADs. We were surprised to find no additional genotype or sex-specific
effects on levels of other cell-signaling proteins that are critical for memory processes;
however, one training session with novel objects prior to tissue collection may not have
been sufficient to drive learning-induced changes in these pathways. Future work should

45

examine multiple time points after a robust learning experience to more definitively
determine whether cell-signaling activity is compromised by APOE4 genotype.
Our finding that dorsal hippocampal ERα levels are increased in E4FADs relative
to E3FADs is consistent with previous work showing that ERα levels are increased in the
AD brain (Ishunina et al., 2003; Ishunina & Swaab, 2003). Caveolin-1 plays a key role in
associating mGluRs with ERα at the cell membrane (Boulware et al., 2013; Razandi et
al., 2002), although caveolin-1 protein levels were unaffected by sex or genotype in the
present study. Therefore, the increase in ERα levels seen among E4FADs relative to
E3FADs suggests that APOE4 may promote an increase in the cytosolic, rather than
membrane, localization of this receptor. Others have posited that estrogens may interact
with ERα to increase levels of apolipoprotein E (apoE), particularly in APOE4 carriers, in
a manner that would make such individuals more vulnerable to disease progression (J.
M. Wang et al., 2006). Although our data lend correlative support to this hypothesis, any
differential effect of APOE on estrogen therapy remains unclear. Notably, our data
indicate that ERβ expression was unaffected by APOE genotype, thus implicating ERα
as a more promising target for estrogen therapy for APOE4 carriers.
Collectively, the results from the present study of 6 month-old EFAD mice suggests
a substantial influence of APOE4 genotype, but not sex, on measures of hippocampusdependent memory, and hippocampal spine density, and protein expression. Of particular
note, APOE4 genotype had detrimental effects on object memory, CA1 spine density,
and dorsal hippocampal levels of synaptic proteins and ERα. E4FAD females additionally
exhibited aberrant GFAP levels and CREB phosphorylation. Future studies are critical to
determining whether other aspects of neural function can account for the sex and APOE
46

genotype interactions observed in humans that increase APOE4+ women’s vulnerability
to AD. Knowing when APOE4 and sex exert detrimental effects is a key knowledge gap,
and the present study is limited by the examination of these variables at a single time
point in EFAD mice. Therefore, next steps should include examining whether APOE4 and
sex negatively impact synaptic integrity and memory at an earlier age, and whether the
possibility exists to reverse or mitigate the course of neurodegeneration modulated by
APOE4 genotype and sex. Pinpointing the time at which memory deficits emerge may
have

therapeutic

potential

in

resolving

memory

neuropathology (Lanfranco et al., 2020; Tai et al., 2014).
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associated

CHAPTER THREE. Defining the impact of APOE genotype and ovariectomy on
anxiety-like behavior in EFAD mice
The primary objective of this aim was to determine whether APOE genotype and
gonadal status (i.e. intact or ovariectomized) act independently or together to modulate
anxiety-like behavior. Interestingly, previous evaluations of anxiety-like behavior in rodent
models of AD have yielded inconsistent and contradictory results. In some cases,
transgenics including APP/PS1 and 5xFAD mice, exhibited decreased or equivalent
anxiety-like behavior in the open field or elevated plus maze relative to wild-type controls
(Arendash et al., 2001; Jawhar et al., 2012; Radde et al., 2006). By contrast, increased
anxiety-like behavior has also been reported, often in the same tasks or animal model
that reportedly exhibited decreased anxiety-like behavior in previous studies (Flanigan et
al., 2014; Lippi et al., 2018; Sterniczuk et al., 2010). Discordant findings in investigations
of anxiety-like behaviors underscore the need for additional attention to be paid to
modeling anxiety-like behaviors in rodent models of AD and determining how risk factors
like APOE genotype, sex, and ovarian hormone loss influence these behaviors within
these models.
Consistent with the human literature, male and female mice expressing APOE4
exhibit increased anxiety-like behavior relative to APOE3 carriers (Robertson et al., 2005;
Siegel et al., 2012). However, whether this between-genotype difference persists in model
in which mice also develop AD-like pathology remains an important question. In addition,
although female sex increases risk for anxiety and for AD in humans, few existing studies
evaluate sex differences in anxiety-like behavior in mouse models of AD. Unfortunately,
many studies that include both males and females do not segregate data by sex, which
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could inadvertently occlude observation of sex differences in anxiety-like behaviors in
these models. Given the differential contributions of sex, as well as APOE3 and APOE4
genotypes, to anxiety in human patients (Michels et al., 2012; Tao et al., 2018), examining
how these factors contribute to anxiety-like behavior against a background of AD
pathology is a crucial step towards targeting anxiety-like symptomology in disease
treatments. Our working hypothesis was that APOE4 genotype and ovariectomy would
increase anxiety-like behavior in EFAD mice.

Materials and methods
Subjects
Female EFAD mice homozygous for APOE3 or APOE4 underwent the same
breeding process and aging process as in aim 1. Mice were housed in groups of 3-5 per
cage (at both UIC and UWM for Experiment 1a, designed to test impact of APOE
genotype on anxiety-like behavior) or singly housed (Experiment 1b, designed to test the
combined impact of APOE genotype and ovariectomy on anxiety-like behavior) and
maintained on a 12 hr light/dark cycle with ad libitum access to food and water for the
duration of the study. Mice were handled for 30 s/day for three days prior to behavior.
Protocols and procedures followed the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and were approved by the UIC Animal Care Committee
and UWM Institutional Animal Care and Use Committee.

49

Surgery
Mice in Experiment 1a did not undergo surgical procedures. Two weeks prior to
behavioral testing, female E3FAD and E4FAD mice in Experiment 1b underwent bilateral
ovariectomy to eliminate ovarian hormones, and were also implanted with bilateral
stainless steel cannulae into the dorsal hippocampus as described previously (Lewis et
al., 2008) for subsequent experiments. During the procedure, mice were anesthetized
with isofluorane (5% for induction, 2% for maintenance) in 100% oxygen. For analgesia,
mice received carprofen MediGel 1 day before and 1 day after surgery, and received a
subcutaneous injection of 5 mg/kg Rimadyl at the start of the surgical procedure.

Open Field
Data were collected during a 5-minute trial, during which mice explored a novel
empty square arena (60 cm x 60 cm x 47 cm). The arena was illuminated by standing
lights to approximately 75 lux. A luxometer was used before training to verify that the four
corners of the OF were evenly illuminated and within 5 lux of each other. OF was used to
measure general locomotor activity and time spent in the perimeter as an indicator of
anxiety-like behavior (Prut and Belzung, 2003). The arena was divided into 16 squares
via an automated grid system using ANYmaze software (San Diego Instruments), which
was also used to record data. Time in the center squares of the arena, distance travelled,
and speed were recorded. More time in the center was indicative of low anxiety levels,
and higher values for distance and speed indicated increased activity (Bailey & Crawley,
2009).
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Statistical analyses
Statistical analyses were performed using GraphPad Prism 8 software. For
Experiment 1a, differences were assessed using two-way ANOVAs with sex and
genotype as between-subject variables. For Experiment 1b, differences were assessed
using two-way ANOVAs with genotype and gonadal status as between-subject variables.
Because APOE4 genotype and female sex are associated with greater anxiety in humans
(Michels et al., 2012; Tao et al., 2018), we hypothesized that female E4FADs would
exhibit the most anxiety-like behavior followed by female E3FADs and male E4FADs, and
then male E3FADs. Due to these specific predictions, significant main effects were
followed by planned Tukey’s post hoc comparisons. Statistical significance was set at p
< 0.05 for all statistical tests. Trends were determined by p < 0.10. Effect sizes were
calculated using η2.

Results
APOE4 genotype increases anxiety-like behavior in the open field relative to
APOE3 genotype
Given the prevalence of anxiety in AD patients (Ferretti et al., 2001; Porter et al.,
2003), particularly APOE4 carriers (Michels et al., 2012), anxiety-like behaviors were
measured in male and female E3FAD (n = 16, male E3FAD; n = 16, female E3FAD) and
E4FAD mice (n = 13, male E4FAD; n = 14, female E4FAD) using the open field (OF).
E4FADs, regardless of sex, spent significantly less time in the center of the OF
than E3FADs (Fig. 10B; genotype effect: F(1, 55) = 6.89, p = 0.01, η2 = 0.11). This effect
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was prominent in E4FAD females, such that female E4FADs spent significantly less time
in the center than female E3FADs (p = 0.04). The main effect of sex and genotype x sex
interaction were not significant.
Females traveled further than males (Fig. 10C; F(1, 53) = 8.0 p = 0.007, η2 = 0.13).
Female E4FADs traveled the furthest, moving longer distances than male E3FADs (p =
0.02). Average speed was also influenced by sex, such that females traveled faster than
males (Fig. 10D; F(1, 53) = 8.07, p = 0.006, η2 = 0.13). As with distance traveled, female
E4FADs traveled significantly faster than male E3FADs (p = 0.02). The main effects of
genotype and genotype by sex interactions were not significant for either measure.
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Fig 10. E4FADs exhibit more anxiety-like behavior in the open field than E3FADs.
(A) Track plots illustrate representative patterns of movement in the open field. (B) E4FAD
females spent less time in the center relative to E3FADs (&p < 0.05, main effect of
genotype; *p < 0.05, female E4FADs vs female E3FADs). (C,D) Female E4FADs traveled
further (##p < 0.01, main effect of sex; *p < 0.05, female E4FAD vs male E3FAD) and
faster on average (##p < 0.01, main effect of sex; *p < 0.05, female E4FAD vs male
E3FAD) than male E3FADs.

Ovariectomy increases anxiety-like behavior in the open field in E3FADs
Because oophorectomy before menopause increases AD risk (Rocca et al., 2007),
and estrogens are anxiolytic (Walf & Frye, 2006), we sought to determine whether loss of
ovarian hormones facilitates increased anxiety-like behavior in the OF in female EFADs.
Here, we hypothesized that female E4FADs would spend significantly less time in the
center of the OF than every other group, and that OVX would exacerbate this effect. Thus,
we tested whether bilateral ovariectomy resulted in decreased time spent in the center of
the OF in the EFAD model by comparing anxiety indices of the intact female E3FAD and
E4FADs from Experiment 1a to OVXed female E3FAD (n = 32) and E4FADs (n=31).
OVXed female EFADs spent significantly less time in the center of the OF relative
to intact female EFADs (Fig. 11B; gonadal status effect: F(1,87) = 16.6, p < 0.0001, η2 =
0.15), and E4FADs spent less time in the center relative to E3FADs (Fig. 11B; genotype
effect: F(1,87) = 4.14, p = 0.045, η2 = 0.04). These effects and their interaction (Fig. 11B;
F(1,87) = 6.98 p = 0.01, η2 = 0.06 ) were driven by intact female E3FADs spending
significantly more time in the center than every other group (p = 0.006 vs OVXed E3FADs;
p = 0.0005 vs intact E4FADs; p = 0.0002 vs OVXed E4FADs). Importantly, no differences
were observed between OVXed E3FAD and E4FAD females, or intact and OVXed
E4FADs, suggesting that OVX induces an E4FAD-like OF phenotype in female E3FADs.
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For distance traveled and average speed, two-way ANOVAs yielded no significant main
effects or interactions, suggesting that all groups traveled similar distances at similar
speeds.

Fig. 11. Ovariectomy induces an APOE4-like anxiety phenotype in E3FAD females.
(A) Track plots illustrate representative patterns of movement in ovariectomized EFADs
in the open field. (B) E3FAD females spent significantly more time in the center than
E4FAD females (&p < 0.05, main effect of genotype), and intact E3FADs spent
significantly more time in the center than OVXed EFADs ($$$p < 0.0001, main effect of
OVX). Intact E3FADs spent significantly more time in the center relative to every other
group (^^p < 0.01, significant interaction; **p < 0.01 vs OVXed E3FADs, ***p < 0.001 vs
intact and OVXed E4FADs). (C,D) Distance traveled and average speed did not differ
among female EFADs regardless of genotype or gonadal status.
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Discussion
Given the prevalence of anxiety in AD patients (Ferretti et al., 2001), understanding
whether genetic or sex-specific factors contribute to anxiety-like symptoms is crucial for
development of therapeutics. The present study tested whether APOE4 genotype, female
sex, and ovarian hormones contribute to increased anxiety-like behavior in a mouse
model of AD designed to reproduce APOE-associated disease risk against a background
of AD-like pathology. We hypothesized that the APOE4 genotype in this model would be
associated with decreased time spent in the center of the OF relative to the APOE3
genotype, and that OVX would be anxiogenic for OF behaviors. Results indicate that
APOE4 genotype was anxiogenic in the OF, as was ovarian hormone loss in female
APOE3 homozygotes. These data provide new insights into factors that may contribute
to anxiety in women with AD, and suggest that hormone therapy may help alleviate
anxiety in some female patients.
In male and female mice expressing human APOE, APOE4 carriers exhibit more
anxiety-like behavior than APOE3 carriers (Robertson et al., 2005; Siegel et al., 2012).
Data from human patients with probable AD mirror findings from animal models, in that
APOE4 is anxiogenic relative to APOE3 (Robertson et al., 2005). These findings are
consistent with our data demonstrating that E4FADs spent less time in the center of the
OF compared to E3FADs, although this effect appears to be driven largely by female
E4FADs. Others have found the APOE4 genotype to be anxiogenic in males in the
elevated plus maze (Robertson et al., 2005). However, our results suggest minimal
differences in OF behavior between male E3FAD and E4FADs, underscoring the need to
use multiple behavioral tasks to provide a more complete understanding of how different
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APOE genotypes influence anxiety-like behaviors. Although the sex x genotype
interaction was not significant, the markedly reduced center time for female E4FADs
relative to E3FADs suggests that female sex may exacerbate anxiety-like behavior in
APOE4 carriers.
We also found that female EFADs were more active than male EFADs, regardless
of genotype, which is consistent with reports that female rodents are more active than
males (Beatty, 1979; Rosenfeld, 2017). Although female E4FADs were the most active,
they also spent the least amount of time in the center of the OF, suggesting that anxiety
about being in a novel environment may have resulted in rapid circling of the periphery in
an attempt to escape.
Our results demonstrating that OVXed E3FADs were more anxious than intact
E3FADs, and similarly anxious to E4FAD females, are consistent with data demonstrating
that OVX increases anxiety-like behavior (de Chaves et al., 2009; Schoenrock et al.,
2016). However, we saw no decrease in time spent in the center of the OF in OVXed
E4FADs relative to intact E4FADs. This similarity may be attributed to the detrimental
impact of APOE4, such that the already low amount of time spent in the center of the OF
in E4FAD females prevented OVX from further decreasing this measure. Given that intact
female E3FADs spent more time in the center of the OF than OVXed female E3FADs,
our data suggest a neuroprotective role for ovarian estrogens against anxiety-like
behaviors. If validated in future studies with other anxiety-like behaviors, then these
findings may suggest that both ovarian status and APOE genotype should be taken into
careful consideration when weighing treatment options for AD patients.
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Future work should also examine whether estrogen replacement is anxiolytic in
E3FADs and E4FADs, and in APOE3 and APOE4 human carriers. Here we employed
only one method of assessing anxiety-like behaviors, and examining additional indices of
anxiety would provide a more complete understanding of contexts under which APOE4
and hormone loss are anxiogenic. Two important potential confounds must be considered
in future experiments examining effects of OVX on anxiety-like behaviors in EFAD mice.
First, mice from Experiment 1b underwent surgical procedures, whereas mice from
Experiment 1a did not. However, two weeks elapsed between surgery and behavioral
testing, which allowed for full recovery prior to OF and should have mitigated any lasting
effects from surgery. Nevertheless, sham OVX and intracranial surgeries would serve as
important controls in future work to support a causative role of OVX and rule out any
detrimental effects of cannulation surgery on brain structures involved in modulating
anxiety. Second, mice from Experiment 1a were group housed, whereas mice from
Experiment 1b were singly housed. It is possible that group housing protected against
anxiety-like behaviors in E3FADs, and that the anxiety-like phenotype present in OVXed
E3FADs cannot be fully attributed to OVX. However, because mice were only singlyhoused for one week prior to testing, chronic or long-lasting effects of single housing,
which is known to increase anxiety-like behaviors, is unlikely to have affected OF
exploration in the present experiment. Nevertheless, disentangling the effects of single
versus group housing in future work would strengthen the conclusion that OVX is
responsible for an increased anxiety-like phenotype in E3FADs.
Given results showing a benefit for the potent estrogen 17β-estradiol (E2) on
cognition and anxiety-like behaviors, E2 may also be therapeutic for anxiety in AD patients
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(Walf & Frye, 2006). Furthermore, researchers should explore whether timing of
administration following gonadectomy impacts the ability of E2 to decrease anxiety-like
behavior, given the critical window for estrogen replacement therapy for other cognitive
behaviors. However, whether estrogen replacement therapy may resolve behavioral
symptomology of AD in APOE4 carriers remains controversial and deserves further study.
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CHAPTER FOUR. Determining whether 17-β estradiol can facilitate memory in
female E3FAD, E3/4FAD, and E4FAD mice
The primary objectives of this study were to determine: 1) whether E2 was of
mnemonic benefit to ovariectomized EFAD females, and 2) whether changes in dendritic
spine density and protein expression underly the beneficial effects of E2 in E3FAD and
E3/4FAD, but not E4FAD females. Because the drop in circulating ovarian hormones is
associated with cognitive disruptions in women (Mitchell & Woods, 2011; Weber et al.,
2014), whether exogenous estrogen replacement is of mnemonic benefit in both normal
and pathological aging has been a long-standing and sometimes controversial question
within the field of cognitive neuroendocrinology (McCarrey & Resnick, 2015). Our own
data show that intracranial administration of estrogens can extend the delay at which
ovariectomized female mice can remember a previously seen object or location (Fortress
et al., 2013; Kim et al., 2016; Taxier et al., 2019). Until the current project, however, we
had not explored whether intrahippocampal E2 was beneficial in a mouse model of AD.
E2 reduces risk for cognitive impairment in APOE4-negative, but not APOE4
positive female patients (Yaffe et al., 2000). Limited available data suggest that E2 may
exert similar effects in animal models of aging or disease. For example, in ovariectomized
macaques, genes upregulated by exogenous estrogen treatment overlap with genes that
are downregulated in brains from human AD patients (Ratnakumar et al., 2019). In the
3xTg-AD mouse model, ovariectomy resulted in cognitive deficits and increased
accumulation of amyloid beta, both of which were prevented by treatment with estrogens
(Carroll et al., 2007). Furthermore, the benefits of E2 in the 3xTg model seem to be
dependent upon treatment initiation during early middle age (Christensen et al., 2020),
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supporting existing evidence from human patients that administration of hormone therapy
must occur during a critical window of time within the onset of menopause or reproductive
aging (Maki, 2013).
In the EFAD model, 3-month old OVXed E2FADs and E3FADs exhibited lower
levels of extracellular amyloid and intracellular amyloid deposition in the hippocampus
and cortex following chronic treatment with E2 (Kunzler et al., 2014). Conversely, 3-month
old OVXed E4FADs treated chronically over the course of 3 months with E2 exhibited
increased extracellular amyloid and intracellular amyloid deposition (Kunzler et al., 2014).
These data implicate APOE2 and APOE3 carriers, but not APOE4 carriers as potential
beneficiaries of E2 treatment. In fact, APOE4 status may render individuals susceptible to
deleterious effects of E2 treatment.
Although promising evidence exists for a favorable modulatory effect of E2 in
E2FAD and E3FAD, but not E4FAD female mice on AD-like pathology (Kunzler et al.,
2014), intermediary factors contributing to the beneficial effects of E2 in E2FAD and
E3FADs, and harmful effects of E2 in E4FADs, remain unidentified. Moreover, whether a
single copy of APOE4, rather than APOE4 homozygosity, renders EFADs less
susceptible to E2 treatment, remains unknown. APOE4 homozygosity is relatively
uncommon in human populations, but even a single copy of APOE4 can magnify AD risk
(Farrer et al., 1997). Whether APOE4 is similarly harmful for memory consolidation and
its associated molecular processes in EFAD heterozygotes represents a key knowledge
gap.
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There is a paucity of data linking molecular mechanisms to the potential mnemonic
benefit of E2 in AD models that account for APOE status. Therefore, the present study
was designed to investigate whether E2 promotes memory consolidation in mice that are
designed to recapitulate APOE-associated disease risk against a background of AD-like
pathology. Our working hypothesis was that E2 would enhance memory in E3FAD and
E3/4FAD, but not E4FAD mice, and that E2 would exert its effects via rapid
phosphorylation of extracellular signal-regulated kinase and other kinases that interface
with the mitogen-activated protein kinase cascade. In addition, based off of previous work
from our lab (Tuscher et al., 2016), we hypothesized that any memory-enhancing effects
of E2 would be associated with an increase in CA1 basal and apical spine density, and
mPFC basal spine density 2 h post-infusion.

Materials and methods
Subjects
Female EFAD mice for the present experiment were homozygous for human
APOE3 (E3FAD) or APOE4 (E4FAD), or had one copy each of APOE3 and APOE4
(E3/4FAD). Breeding, transfer from UIC to UWM, and aging occurred as in Aims 1 and 2.
Prior to surgery, mice were housed in groups of up to 5 per cage, and were singly-housed
following cannulation and ovariectomy. Mice were maintained on a 12 hr light/dark cycle
with ad libitum access to food and water for the duration of the study. Protocols and
procedures followed the National Institutes of Health Guide for the Care and Use of
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Laboratory Animals and were approved by the University of Wisconsin-Milwaukee
Institutional Animal Care and Use Committee.

Surgeries
Mice received a 5mg/kg dose of subcutaneous Rimadyl for pain management at
the start of the surgical procedure. Mice were anesthetized with isofluorane in 100%
oxygen (5% for induction, 2% for maintenance) and placed in a stereotaxic apparatus
(Kopf instruments) for ovariectomy (OVX) and cannula implantation in the same surgical
session (Lewis et al., 2008). Stainless steel bilateral guide cannulae (C232GC, 22 gauge;
Plastics One) were implanted into the DH (-1.7 mm AP, ± 1.5 mm ML, and -2.3 mm DV)
and affixed to the skull using dental cement (Darby Dental). Dummy cannulae (C232DC;
Plastics One) were used to prevent cannulae clogs. Mice received MediGel carprofen
(ClearH20) for postsurgical analgesia and were given one week to recover prior to the
start of behavioral testing.

Drugs and Infusions
Hydroxypropyl-β-cyclodextrin

(HBC)-encapsulated

E2

(Sigma-Aldrich)

was

dissolved in 0.9% sterile saline to a concentration of 10μg/μl and was infused at a rate of
0.5μl/min for 1 min/hemisphere (Fortress et al., 2013). Vehicle-treated mice received HBC
(Sigma-Aldrich) dissolved in saline to the same concentration of cyclodextrin as in the E2
solution. For behavioral experiments, mice received an infusion of vehicle or E2
immediately post-training. Two weeks following the conclusion of behavioral experiments,
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mice were reinfused with the same treatment they had previously received, and tissue
was taken 5 min following infusion for Western blotting or 2 hr following infusion for Golgi
impregnation and spine counting.

Behavioral Tasks
Object recognition (OR) and object placement (OP) were conducted as described
in Aim 1. Here, rather than returning mice to their home cages immediately following
training, mice received DH infusion of veh or E2 and were then returned to their home
cage. Although vehicle-treated OVXed wild-type mice typically remember a previouslyseen object or the location of a previously-seen object at a 24 hr (OR) or 4 hr (OP)
delay, we previously showed in Aim 1 hat only male E3FADs, and not female E3FADs
or E4FADs, remember the previously seen object or location (Taxier et al., submitted)
when tested at these same delays. Thus, given that female E3FADs and E4FADs don’t
remember at a 24 h (OR) or 4 h (OP) delay, we tested animals in the present
experiment using these same delays in order to test whether DH E2 infusion could
facilitate memory consolidation.

Western Blotting
Two weeks following the conclusion of behavioral testing, a subset of mice (1012/group) were infused with vehicle or E2. Mice were cervically dislocated and
decapitated 5 min post-infusion. Brains from each group were extracted and bilateral DH
was immediately dissected and frozen at -80°C. Western blotting was conducted as
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described previously (Boulware et al., 2013; Fernandez et al., 2008; Fortress et al.,
2013b; Kim et al., 2016; Koss et al., 2018; Taxier et al., 2019; Zhao et al., 2012). To
prepare tissue samples for Western blot, tissues were resuspended 1:25 weight/volume
in lysis buffer containing PMSF and a protease inhibitor cocktail (Sigma-Aldrich Corp.)
and homogenized using a probe sonicator (Branson Sonifier 250). Homogenates are
electrophoresed on 10% TGX (Tris-Glycine eXtended) stain-free precast gels (Bio-Rad)
and transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad) using the
TransBlot Turbo system (Bio-Rad). Total protein transfer was verified using a ChemiDoc
MP gel imager (Bio-Rad).
The following primary antibodies were used, and blots incubated overnight at 4°C:
phospho-ERK (#9101, 1:2000), total-ERK (#9102, 1:2000), phospho-PI3K (#177366,
1:1000), total PI3K (#4257,1:1000), synaptophysin (#4329 1:1000), PSD95 (#2507;
1:1000), GFAP (#12389; 1:1000), Beta Actin (#4970, 1:1000), Cell Signaling Technology;
ERα (H-184, 1:1000), Santa Cruz Biotechnology; ERβ (#PA1-310B, 1:1000), Thermo
Fisher; and Iba1 (#016-20001, 1:1000), FujiFilm Wako Chemicals. The following day, all
blots were incubated at room temperature with a rabbit secondary antibody (#7074,
1:5000, Cell Signaling Technology. Densitometry was performed using Image Lab
software (Bio-Rad Image Lab v 5.2). Phosphorylated proteins were normalized to their
respective total proteins. The remaining blots were stripped and reprobed for β-Actin
(#4967, 1:1000, Cell Signaling Technology) for protein normalization. Data are expressed
as average volume intensity as a percentage compared to vehicle-treated OVXed E3FAD
females.
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Golgi Impregnation and Spine Counting
Whole brains (n=4-9/group) were collected for Golgi impregnation two weeks
following the conclusion of behavioral testing. Mice were cervically dislocated and
decapitated 2 h following DH infusion of veh or E2. The 2 h time point was chosen because
previous work from our lab and others indicates that DH infusion of E2 increases DH and
mPFC dendritic spine density at this delay (Tuscher et al., 2016). Golgi staining was
performed as described previously and above as in Aim 1 (Frankfurt et al., 2011; Kim et
al., 2019; Taxier et al, submitted; Tuscher et al., 2016a) using the Rapid Golgi Stain Kit
(FD Neuro Technologies).
As in aim 1, secondary basal dendrites and tertiary apical dendrites were counted
from pyramidal neurons in the dorsal hippocampal CA1 and layer II/III of the mPFC under
an Olympus BX51WI microscope (100x with oil) using NeuroLucida (v 11.08, MBF
Bioscience). Accuracy of DH cannula placement was visually validated by examining
sections containing DH tissue.
Statistical analyses
All statistical analyses were conducted using GraphPad Prism 9 software (La Jolla,
CA). In order to assess within-group learning for OR and OP, one-sample t tests were
used to determine whether the time spent with each object during testing significantly
differed from chance (15 s). Differences in memory between groups were assessed using
two-way ANOVAs with treatment and genotype as between-subject variables. Similar
two-way ANOVAs were used to analyze Western blot and dendritic spine density data.
Significant main effects were and followed by Tukey’s post hoc tests for OR, OP, Western
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blot, and dendritic spine data. Statistical significance was set at p < 0.05 for all statistical
tests, and trends were determined by p < 0.10.

Results
Object Recognition
To determine whether APOE genotype influences the ability of E2 to facilitate memory
for a previously seen object or location, OVXed female E3FAD, E3/4FAD, and E4FAD
mice (n = 11-21/group) were tested in the OR and OP tasks after receiving a post-training
bilateral dorsal hippocampal infusion of vehicle or E2. Our published data demonstrate
that wild type C57BL/6 mice remember a previously seen object 24 h later (OR) and
location 4 h later (OP) (Fortress et al., 2013; Taxier et al., 2019; Tuscher et al., 2018). In
addition, we showed in the second chapter of this dissertation that intact untreated female
E3FADs and E4FADs are memory-impaired at these delays (Taxier et al, submitted). In
the present study, we chose delays of 24 h (OR) and 4 h (OP) test whether E2 treatment
can restore OR and OP memory to levels similar to wild type mice.
In the object recognition task, E2-treated E3FADs (Fig. 12A; t(15) = 3.406, p = 0.004)
and E3/4FADs (Fig. 12A; t(10) = 2.745, p = 0.0201) spent significantly more time than
chance (15 s) with the novel object during testing, indicating intact memory for the identity
of the training objects. By contrast, vehicle-treated E3FADs, E3/4FADs, and E4FADs, as
well as E2-treated E4FADs, did not spend significantly more time than chance with the
novel object during testing, suggesting that two copies of the APOE4 allele prevented E2
from facilitating memory. A two-way ANOVA revealed a main effect of E2 treatment (Fig.
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12A; F(1, 89) = 9.614 , p = 0.003), as well as a significant genotype x treatment interaction
(F(2, 89) = 4.821 , p = 0.01) for time spent with the novel object during testing. These effects
seemed to be driven by the beneficial effect of E2 in E3FADs and E3/4FADs, given that
vehicle-treated E4FADs and E2-treated E4FADs spent similar amounts of time with the
novel object during testing. Planned post hoc comparisons support the notion that E2treated E3FAD and E3/4FADs drove the main effect of treatment, as there was a
significant between-group difference for vehicle-treated E3/4FADs versus E2-treated
E3/4FADs (p < 0.031), and a trend for a difference between vehicle-treated E3FADs and
E2-treated E3FADs (p = 0.07).
Interestingly, time to accumulate 30 seconds of object exploration during testing was
significantly modulated by genotype (Fig 12C; F(2, 86) = 11.93 , p < 0.0001), such that
E4FADs took significantly less time to reach 30 seconds of object exploration relative to
other groups. E4FADs treated with E2 were particularly fast to complete object
exploration, as demonstrated by post hoc comparisons (Fig 12C; p = 0.002 vs E2-treated
E3FADs, and p = 0.0004 vs E2-treated E3/4FADs).
Object Placement
The object placement task yielded similar results to the object recognition task, in that
E2-treated E3FADs (Fig. 12B; t(12) = 3.741, p = 0.003) and E3/4FADs (Fig. 12B; t(10) =
5.644, p = 0.0002) spent significantly more time than chance (15 s) with the moved object
during testing, indicating intact memory for the identity of the training objects.
Furthermore, vehicle-treated E3FAD, E3/4FAD, and E4FADs, as well as E2-treated
E4FADs, did not spend significantly more time than chance with the moved object during
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testing, again suggesting that APOE4 homozygotes are unresponsive to the mnemonic
benefits of E2. As with OR, a two-way ANOVA revealed a main effect of treatment (Fig.
12B; F(1, 88) = 8.183 , p = 0.005), as well as a significant genotype x treatment interaction
(Fig. 12B; F(2, 88) = 3.591 , p = 0.032). However, unlike OR, there was also a significant
main effect of genotype (Fig. 12B; F(2, 88) = 10.72 , p < 0.0001), such that E3FAD and
E3/4FADs had superior memory for moved objects relative to E4FADs. The main effects
of treatment and the significant genotype x treatment interaction seemed to be driven by
the beneficial effect of E2 in E3 and E3/4FADs, given that vehicle-treated E4FADs and
E2-treated E4FADs spent similar amounts of time with the novel object during testing. The
main effect of genotype appeared to be driven by the overall poor performance of
E4FADs, regardless of treatment. In support of these conclusions, planned post hoc
comparisons indicated that E2-treated E3FADs spent significantly more time with the
novel object than E2-treated E4FADs (Fig. 12B; p = 0.002). Similarly, E2-treated
E3/4FADs spent significantly more time with the novel object than E2-treated E4FADs
(Fig. 12B; p = 0.0009).
Similarly to OR, time to accumulate 30 seconds of object exploration during testing
was significantly modulated by genotype (Fig 12D; F(2, 89) = 8.765 , p = 0.0003), such that
E4FADs took significantly less time to reach 30 seconds of object exploration relative to
other groups. Again, as with OR, the effect of genotype on time to complete the task was
particularly driven by the rapid task completion of E2-treated E4FADs (Fig 12D; p = 0.007
vs E2-treated E3FADs).
Combined, data from both OR and OP tasks suggest that E2 supports memory
consolidation in OVXed E3FAD, and E3/4FAD, but not E4FAD, females. Furthermore,
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E4FAD homozygosity may contribute to a hyperactivity phenotype in OVXed females,
given that E4FADs completed the object tasks more quickly than EFADs of other
genotypes. The observed increased activity in E4FADs from the present experiment is
also consistent with the increase in speed seen in the OF task in the previous chapter.

Fig.12 E2 facilitates object recognition and spatial memory formation in OVXed
E3FADs and E3/4FADs. E3FADs and E3/4FADs treated with E2 spent significantly more
time than chance (dashed line at 15 sec; ^ p < 0.05, ^^ p < 0.01, ^^^ p < 0.001) with the
novel (A) and moved (B) objects during testing. E2-treated EFADs spent more time than
veh-treated EFADs with the novel (A) or moved object (B) ($$p < 0.01 = main effect of
treatment; %p< 0.05 = genotype x treatment interaction). E2-treated E3/4FADs spent more
time with the novel object (A) than veh-treated E3/4FADs ( *p < 0.05). E3FADs and
E3/4FADs spent more time with the moved object (B) than E4FADs (&&&&p < 0.0001 =
main effect of genotype). E2-treated E3FADs spent more time with the moved object (B)
than E2-treated E4FADs (**p < 0.01), as did E2-treated E3/4FADs (***p < 0.001). E4FADs
took less time to complete either task (A, &&&&p < 0.0001 = main effect of genotype; B,
&&&p < 0.001 = main effect of genotype). E -treated E4FADs took less time than E 2
2
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treated E3/4FADs and E3FADs to accumulate 30s in OR (C; **p < 0.01). E2-treated
E4FADs took less time to accumulate 30s in OP than E2-treated E3FADs (D; **p < 0.01)
Bars represent mean ± standard error of the mean (SEM).

Western Blotting
Cell signaling and synaptic proteins
Because the memory-enhancing effects of E2 are dependent upon the rapid
activation of cell signaling cascades including ERK/MAPK and PI3K/Akt signaling within
the DH, we examined expression of protein kinases and the synaptic protein PSD95, a
downstream target of memory-related kinase activity (Yoshii & Constantine-Paton, 2014),
in the DH of OVXed E3FAD, E3/4FAD, and E4FAD females 5 minutes after E2 infusion.
Significant results are reported below in the text, and nonsignificant data are reported in
Table 4.
Two-way ANOVAs revealed a significant main effect of E2 treatment, but no effect
of genotype or treatment x genotype interaction on DH pPI3K expression (Fig. 13B; F(1,50)
= 13.17, p = 0.0007). Planned post hoc comparisons revealed that E2-treated E3FADs
had significantly less pPI3K than vehicle-treated E3FADs (Fig. 13B; p = 0.018). A
significant main effect of E2 treatment, while modest, was also present for pNR2B (Fig.
13C; F(1,50) = 4.216, p = 0.045), in addition to a main effect of genotype (Fig. 13C; F(2,50)
= 9.294, p = 0.0004). Planned post hoc comparisons revealed that vehicle-treated
E3FADs had significantly more pNR2B than vehicle-treated E4FADs (Fig. 13C; p =
0.001).
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Table 4. Proteins in CA1 unaffected by E2 treatment or APOE genotype
Protein

Veh

E3FAD

E2

Veh

E3/4FAD

E2

Veh

E4FAD

E2

71

pERK42
pERK44

100.0 ± 10.56
100.0 ± 9.32

93.21 ± 10.05
119.5 ± 8.41

109.39 ± 20.88
97.37 ± 12.2

112.559 ± 16.44
124.85 ± 9.37

109.447 ± 15.776
133.63 ± 18.73

110.17 ± 14.46
111.44 ± 9.96

pJNK46
pJNK56

100.0 ± 2.05
100.0 ± 5.86

89.52 ± 3.88
89.7 ± 7.51

93.15 ± 6.28
96.39 ± 8.67

94.97 ± 4.5
90.6 ± 7.57

102.83 ± 5.25
97.68 ± 7.94

94.02 ± 4.6
87.35 ± 8.05

pβcatenin

100.0 ± 6.88

94.92 ± 6.73

109.42 ± 10.78

95.9 ± 8.73

94.29 ± 10.64

91.11 ± 5.52

pCofilin

100.0 ± 3.62

85.02 ± 8.66

78.35 ± 15.64

89.64 ± 16.62

96.08 ± 12.12

98.84 ± 13.47

pGSK3β

100.0 ± 7.91

100.09 ± 11.04

97.95 ± 4.56

98.2 ± 10.44

107.41 ± 9.13

93.69 ± 7.85

pPKC

100.0 ± 9.79

91.15 ± 9.06

97.99 ± 6.85

94.95 ± 4.43

101.8 ± 10.52

96.97 ± 5.44

Iba1

100.0 ± 11.01

134.75 ± 24.5

109.94 ± 9.58

112.39 ± 18.71

100.63 ± 9.61

117.52 ± 17.78

GPER

100 ± 4.43

92.62 ± 8.15

85.54 ± 9.42

85.47 ± 10.92

81.79 ± 7.11

88.86 ± 6.58

ERβ

100 ± 4.57

94.71 ± 8.32

109.64 ± 6.68

97.91 ± 4.36

98.69 ± 6.38

100.54 ± 5.89

* All proteins normalized to vehicle-treated E3FADs, whose values were set to 100.

Values represent the mean % immunoreactivity (± SEM) for the target protein divided by β-actin (Iba1, GPER, ERβ) or
unphosphorylated total protein (all phospho proteins).

There was main effect of genotype, but not treatment, nor an interaction, for pAkt
(Fig. 13D; F(2,50) = 9.294, p = 0.0004), which was in part driven by elevated pAkt in E2treated E3FADs relative to E2-treated E4FADs (Fig. 13D; p = 0.03). Similarly, there was
a main effect of genotype, but not treatment, nor an interaction, for pCREB (Fig. 13E;
F(2,47) = 8.81, p = 0.0006), which was oddly driven by elevated levels of pCREB in both
vehicle-treated E3/4FADs (Fig. 13E; p = 0.033 vs vehicle-treated E4FADs) and E2-treated
E3/4FADs (Fig. 13E; p = 0.041 vs E2-treated E3FADs).
Lastly, a two-way ANOVA revealed main effects of genotype (Fig. 13F; F(2,48) =
6.582, p = 0.003) and treatment (Fig. 13F; F(1,48) = 18.03, p < 0.0001), but no genotype x
treatment interaction, on levels of DH PSD95. Planned post hoc comparisons revealed
that vehicle-treated E3FADs had significantly more PSD95 than E2-treated E3FADs (Fig.
13F; p = 0.008).
Glial proteins
Mounting evidence suggests that glial dysfunction is a prominent feature of AD
(Heneka et al., 2015). Therefore, we looked at levels of glial proteins in the DH of EFAD
mice following E2 treatment. There was a significant main effect of genotype on DH levels
of the astrocytic protein GFAP (Fig. 13G; F(2,48) = 4.232, p = 0.02) such that E4FADs had
higher levels of GFAP than mice of other genotypes, but no post hoc comparisons were
significant. There were no significant main effects for the microglial protein Iba1 (Table
4).
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Fig. 13 E2 treatment and APOE genotype modulate protein expression in the DH
of OVXed EFAD mice. (A) Representative blots illustrate relative group differences in
protein expression. Levels of pPI3K (A), pNR2B (C), and PSD95 (F) were decreased
following E2 treatment ($p < 0.05, $$$p < 0.001, $$$$p < 0.0001 = main effect of treatment).
Levels of pNR2B (C), pAkt, and PSD95 (F) were decreased in E4FADs relative to other
genotypes (&&p < 0.01, &&&p < 0.001 = main effect of genotype). Levels of pCREB (E)
were higher in E3/4FADs relative to other groups (&&&p < 0.001 = main effect of genotype).
Levels of GFAP were higher in E4FADs relative to other groups (&p < 0.05 = main effect
of genotype). * p < 0.05, ** p < 0.01, *** p <0.001 = between-group differences.
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Estrogen receptors
Because we previously saw that APOE4 increased ERα expression in the DH of
intact EFADs in the experiments described in the second chapter of this dissertation, we
aimed to characterize expression of this protein, and other estrogen receptors, in OVXed
EFADs treated with E2. A two-way ANOVA revealed a significant main effect of genotype
on levels of ERα (Fig. 14B; F(2,48) = 6.956, p = 0.002), driven by elevated ERα in E4FADs
relative to vehicle-treated E3FADs (p = 0.052 vehicle-treated E3FADs vs vehicle-treated
E4FADs; p = 0.019 vehicle-treated E3FADs vs E2-treated E4FADs). There were no
significant differences in DH protein expression of either ERβ or GPER (Table 4).
Collectively, Western blot results suggest that both E2 treatment and genotype
differentially affect protein expression in the DH of EFAD mice, although they do not
interact to modulate protein expression of any of the measured markers. Contrary to our
hypothesis, E2 treatment did not increase levels of phosphorylated kinases or synaptic
proteins in the DH. In fact, main effects of E2 treatment on levels of pAkt, pNR2B, and
PSD95 were the opposite of what was expected, in that E2 treatment decreased levels of
these markers. For the most part, genotype effects were more consistent with
expectations in that levels of pNR2B, pAkt, and PSD95 appeared to be diminished in
E4FADs relative to other groups. Additionally, E4FADs exhibited elevated levels of ERα
relative to other genotypes, and although not significant, heightened GFAP, which is
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consistent with data from Chapter 2 of the dissertation. Most surprisingly, levels of pCREB
were increased in E3/4FADs relative to other genotypes.

Fig 14. Expression of estrogen receptors in the DH of OVXed EFAD mice. Only ERα
(B) was affected by APOE genotype (&&p < 0.01 = main effect of genotype). Vehicletreated E3FADs had significantly less ERα than E2-treated E4FADs (*p < 0.05). Levels of
ERβ and GPER were unaffected by treatment or genotype.
Dendritic Analyses
We next examined apical and basal dendritic spine density in hippocampal area
CA1 and in the prelimbic/infralimbic area of the mPFC to assess whether APOE genotype
influences the ability of E2 to increase dendritic spine density 2 h following DH infusion.
There were no effects of genotype or E2 treatment, nor an interaction, on mPFC apical
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spines (Table 5). Treatment and genotype effects on CA1 apical, and CA1 and mPFC
basal spines, are detailed below.

Fig 15. Intrahippocampal E2 increases CA1 apical spine density in OVXed E3FAD
and E3/4FAD mice. Total CA1 apical dendritic spine density (A) was increased 2 h
following E2 infusion into the DH ($$p < 0.01 = main effect of treatment) and was
diminished in E4FADs relative to other groups (&p < 0.05 = main effect of genotype). E2
increased CA1 apical stubby spines (B), whereas E4FAD genotype diminished stubby
spines ($p < 0.05 = main effect of treatment, &&p < 0.01 = main effect of genotype)

CA1
A two-way ANOVA revealed significant main effects of genotype (Fig. 15A; F(2,30)
= 3.635, p = 0.039) and E2 treatment on CA1 apical spine density (Fig. 15A; F(1,30) = 8.220,
p = 0.008), but no genotype x treatment interaction. Further analysis by spine subtype
revealed no significant effects of genotype or treatment, nor interactions, on CA1 apical
thin or mushroom spines (Table 5). However, there was a significant main effect of
genotype (Fig. 15C; F(2,31) = 7.374, p = 0.002), and of treatment (Fig. 15C; F(1,31) = 7.09,
p = 0.012) on CA1 apical stubby spines.
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Fig 16. OVXed E4FADs have lower CA1 basal spine density than other EFADs. Total
CA1 basal spine density (A), basilar thin spine density (B), and basilar stubby spine
density (C) was decreased in E4FADs, regardless of treatment (&p < 0.05, &&p < 0.01 =
main effect of genotype). E2-treated E3FADs had more mushroom spines than E2-treated
E4FADs (%p < 0.05 = significant genotype x treatment interaction). (*p < 0.05, **p < 0.01
= significant between-group differences).
A two-way ANOVA revealed a significant main effect of genotype (Fig. 16A; F(2,31)
= 7.774, p = 0.002), but no significant effect of treatment nor a genotype x treatment
interaction on CA1 basal spine density. The main effect of genotype was primarily driven
by elevated dendritic spine density in E2-treated E3FADs, who had significantly higher
basal spine density than E2-treated E4FADs (Fig. 16A; p = 0.002). Further analysis by
spine subtype revealed that the main effect of genotype on total CA1 basal spine density
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was driven by significant effects of genotype on CA1 basal thin spines (Fig. 16B; F(2,31) =
7.887, p = 0.002) and stubby spines (Fig. 16C; F(2,31) = 4.49, p = 0.019). The significant
effect of genotype on CA1 thin basal spine density was driven by elevated thin basal
spines in E2-treated E3FADs relative to E2-treated E4FADs (Fig. 16B; p = 0.013). There
was a significant genotype x treatment interaction for levels of CA1 basal mushroom
spines (Fig. 16D; F(2, 30) = 5.151, p = 0.012), which was driven by significantly more
mushroom spines in E2-treated E3FADs relative to E2-treated E4FADs (Fig. 16D; p =
0.012).
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Table 5. CA1 and mPFC spine density measures unaffected by E2 treatment or genotype
Brain
region

Spine type

CA1

Apical thin

Veh
4.10 ± 0.27

E2
4.46 ± 0.33

Veh
4.06 ± .28

E2
4.02 ± 0.11

Veh
4.26 ± 0.27

E2
4.32 ± 0.21

Apical mushroom

3.45 ± 0.34

3.23 ± 0.34 3.30 ± 0.23

15.6 ± 0.38

3.52 ± 0.78

3.20 ± 0.11

Apical total

11.6 ± 0.88 10.35 ± 0.46 11.43 ± .95 10.03 ± 0.72

10.19 ± 0.85

9.84 ± 0.48

Apical thin

2.74 ± 0.24

2.27 ± 0.06 2.41 ± 0.26

2.24 ± 0.10

2.75 ± 0.28

2.51 ± 0.14

Apical stubby

5.32 ± 0.48

4.77 ± 0.32 5.42 ± 0.43

4.95 ± 0.59

4.59 ± 0.55

4.46 ± 0.38

Basal stubby

7.36 ± 0.46

6.63 ± 0.28 6.80 ± 0.26

6.95 ± 0.57

7.82 ± 0.38

6.79 ± 0.24

Basal mushroom

2.84 ± 0.20

2.96 ± 0.23 2.42 ± 0.32

2.73 ± 0.50

2.32 ± 0.27

2.61 ± 0.29

mPFC

E3FAD
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Values represent mean spines/10 µM ± SEM.

E3/4FAD

E4FAD

Combined, dendritic spine density analyses from CA1 of EFADs treated with E2 suggest
that E2 may exert its memory-enhancing effects via increased CA1 apical spine density,
particularly via its effects on apical stubby spines. The significant effect of genotype on
CA1 basal spines mirrors the significant effect of genotype on CA1 basal spines seen in
the experiments described in Chapter 2 of this dissertation, in that E4FADs exhibited
markedly decreased basilar dendritic spine density relative to E3FADs. The genotype x
treatment interaction effect on CA1 basal mushroom spines raises the important
possibility that E2 facilitates memory via increased CA1 basal mushroom spine density in
E3FADs. Conversely, E4FAD homozygosity may promote an E2-induced decrease in
basilar mushroom spine density, and a corresponding decrease in cognitive capacity.

mPFC
A two-way ANOVA revealed a trend towards a significant main effect of genotype
(Fig. 17A; F(2,

30)

= 3.178, p = 0.055), but not treatment nor a genotype x treatment

interaction, for total mPFC basal spines. As determined by subsequent analyses on
dendritic spine subtypes, this trend towards a main effect of genotype on total mPFC
basal spines was driven by a significant main effect of genotype on basal mPFC thin
spines (Fig. 17B; F(2, 30) = 5.212, p = 0.011). Although no post hoc comparisons were
significant, E3FADs generally had elevated mPFC basal thin spines relative to EFADs of
other genotypes, regardless of treatment. There were no significant genotype, treatment,
nor genotype x treatment effects on levels of mPFC basal stubby (Table 5) or mushroom
spines (Table 5).
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Fig. 17. E3FADs have more mPFC basal spines than E3/4FADs and E4FADs. mPFC
basal spines (A; &p = 0.055) and thin spines (B) were modestly impacted by genotype (B;
&p < 0.05).

The lack of genotype or treatment effects on mPFC apical spine density (Table 5),
and modest genotype effects on mPFC basal spine density indicate that the memoryenhancing effects of E2 on E3FADs and E3/4FADs are not mediated through changes in
mPFC spine density. The modest effect of genotype on mPFC basal spines, both total
and thin, suggests that E3FADs have heightened levels of basal spines relative to
E4FADs, which is consistent with our findings in experiments described in Chapter 2 of
this dissertation.

Discussion
Because APOE4 status and female sex are unmodifiable risk factors that act
synergistically to increase AD risk, evaluating interventional approaches that might benefit
female APOE4 carriers is a crucial step towards providing individualized treatment to AD
patients. Here, we investigated whether APOE genotype interacts with the ability of E2 to
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promote memory consolidation, modulate protein expression, and increase dendritic
spine density in an EFAD mouse model of AD designed to model APOE-associated
disease risk. We hypothesized that E2 would have the most profound effects in OVXed
E3FADs and E3/4FADs such that DH infusion of E2 would promote memory
consolidation, activate cell signaling cascades known to be involved in the memoryenhancing effects of E2, and increase dendritic spine density in both the mPFC and DH.
We also hypothesized that E2 would either have reduced or no efficacy in OVXed
E4FADs. Consistent with this hypothesis, we found that DH infusion of E2 facilitated object
memory consolidation in OVXed E3FADs and E3/4FADs, but not E4FADs, indicating that
two copies of the APOE4 allele results in lower susceptibility to the memory-enhancing
effects of E2. The memory-enhancing effects of E2 were associated with an increase in
total CA1 apical spine density. However, the memory-enhancing benefits of E2 were not
linked to an increase in cell-signaling kinase phosphorylation as predicted; indeed, in
some instances E2 decreased kinase phosphorylation or had no effect, regardless of
APOE genotype. APOE4 genotype alone, in the absence of an E2 effect, modulated
several spine parameters and levels of proteins in the DH. We observed only a single
genotype x treatment interaction, suggesting that E2 increases basilar mushroom spines
in CA1 in E3FADs, but decreases this subtype in E4FADs.
Although others have shown a potential benefit for chronic E2 treatment for
decreasing amyloid accumulation in the EFAD model (Kunzler et al., 2014) and in the
3xTg model of AD (Carroll et al., 2007), our data are the first to demonstrate that a single
acute dose of E2 can facilitate memory consolidation in OVXed E3FAD and E3/4FAD, but
not E4FAD mice. Previous work demonstrated that chronic E2 treatment initiated in 382

month-old OVXed EFADs can significantly reduce amyloid burden (Kunzler et al., 2014).
Our finding that E3FAD and E3/4FAD mice remain susceptible to the beneficial effects of
a single acute dose of E2 until at least 6 months of age, when there is already substantial
development of AD-like pathology (Tai et al., 2017), is particularly striking. Whether
APOE4-negative patients with AD can benefit from E2 treatment after substantial disease
progression remains an important question.
Importantly, our results also suggest that individuals carrying a single copy of the
APOE4 allele may still benefit from the cognitive benefits of E2 treatment, whereas
individuals with two copies would not. This finding is somewhat consistent with data from
human patients, from which the conclusion is sometimes reached that estrogens are
ineffectual or in some instances harmful for cognition in APOE4 carriers (Burkhardt et al.,
2004; Kang & Grodstein, 2012). Others have reported neuroprotective effects and
cognitive benefits of estrogens in human APOE4 carriers, especially when treatment is
initiated within a critical window (Jacobs et al., 2013; Mahoney et al., 2020). More work
remains to determine what factors mediate the neuroprotective properties of E2 in APOE4
carriers.
Protein expression data from the present study did not mirror the beneficial effects
of E2 on memory consolidation. For instance, levels of protein kinase phosphorylation
were either opposite of what was hypothesized or unchanged in response to treatment
with E2. For example, levels of pPI3K, pNR2B, and PSD95, all of which are activated by
E2 in young wild type mice (Akama & McEwen, 2003; Fan et al., 2010; Jie et al., 2018),
were reduced by E2 in the present experiment, particularly in E3FAD and E3/4FAD mice.
One possible explanation for these findings is that E2 is functioning to depress
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hyperexcitability or abnormally high kinase activity in E3FAD and E3/4FAD mice.
However, given that E2 treatment reduced levels of these proteins to amounts akin to
those present in E4FADs, regardless of treatment status, this possibility seems unlikely.
Another potential explanation for an E2-induced depression of phosphorylated kinase
activity is that levels of total protein kinases are different across genotypes, which we did
not capture because we looked at the ratio of phosphorylated protein relative to the total
protein. Additional analyses directly comparing expression levels of the total form of each
protein kinase normalized to Beta Actin or another housekeeping protein could answer
whether levels of total protein kinase are different across genotypes. This type of analysis
could also aid in interpreting the effects of APOE genotype and E2 treatment on levels of
pCREB, which were confusingly high in E3/4FADs, regardless of treatment status,
relative to other groups. Another possibility explaining the lack of an E2 effect on several
kinases is that the dynamics of protein kinase phosphorylation are distinct in EFAD mice
from what we typically see in healthy young wild-type mice. That is, perhaps the initiation
of protein kinase phosphorylation is slower, or more transient, in the EFAD brain. Taking
tissue from these mice at multiple time points post E2-infusion, rather than the single time
point taken here, would help elucidate the time course of kinase phosphorylation events
in the EFAD model.
Genotype effects on levels of hippocampal proteins were more consistent with
expectations, in that E4FADs had elevated GFAP and ERα expression relative to other
genotypes, as in experiments from Chapter 2 of the dissertation. These data suggest that
E4FADs may be rendered less susceptible to the beneficial effects of E2 because of
elevated astrogliosis. Interestingly, although E2 interacts with ERα to facilitate memory
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consolidation in healthy young wild-type mice (Boulware et al., 2013), here it seems that
elevated ERα may have a negative effect on memory consolidation. Consistent with our
own finding, others have shown that ERα is elevated in the hippocampus of AD patients,
particularly APOE4 carriers (Ishunina & Swaab, 2003).
Although E2 treatment effects on hippocampal protein levels were unclear and
contradictory to our hypotheses, dendritic spine data were more consistent with the
behavioral effects in the present study. In particular, E2 increased CA1 apical spine
density, an effect that, while not significant by post hoc comparisons, was most
pronounced in E3FAD and E3/4FADs. The E2-facilitated increase in CA1 apical dendritic
spine density in the present study is consistent with previous research from our lab
showing that CA1 apical spine density is increased 2 hours following E2 infusion in young
wild-type OVXed female mice (Tuscher et al., 2016). We also showed that E2 increased
CA1 apical stubby spine density in EFADs. Although thin spines are typically considered
to be more dynamic, previous work in another AD model suggests that stubby spines take
on a more dynamic role in pathological conditions (Spires-Jones et al., 2007). Therefore,
the increase in apical stubby spines in CA1 may reflect ongoing spine remodeling or
spinogenesis stimulated by E2. Interestingly, E2 also increases CA1 and mPFC basal
spines 2 hours post intrahippocampal E2-infusion in young wild-type mice (Tuscher et al.,
2016). However, we did not see a corresponding increase in CA1 and mPFC basal spines
following E2 infusions in E3FADs or E3/4FADs as in wild-type mice, which may be
reflective of reduced interactions or connectivity between mPFC and CA1 in E2-treated
EFADs.
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Genotype modulated spine density in a manner largely consistent with our
hypotheses, in that genotype effects on CA1 apical, CA1 basal, and mPFC basal spines
were seemingly driven by increased dendritic spine density in E3FADs relative to other
groups, or decreased dendritic spine density in E4FADs relative to other groups, which
may have contributed to their impaired memory consolidation. The main effect of
genotype on basilar thin spine density in CA1 is of particular interest because post hoc
comparisons indicated that E2-treated E3FADs had the highest density of this subtype.
Our data are consistent with previous work showing that treatment with E2 facilitated
cognitive function in aged rhesus monkeys, an effect dependent upon increased thin
spine density (Hao et al., 2006). Furthermore, our data fit with the notion that thin spines
are thought to be “learning spines,” or transient protrusions that often evolve into more
mature, mushroom or “memory” spines (Bourne & Harris, 2007).
The most striking of our observed effects on dendritic spine density was our finding
of a sex x treatment interaction on CA1 basal mushroom spines. This finding, in which
E2-treated E3FADs had the highest number of CA1 basal mushroom spines, whereas E2treated E4FADs had the lowest, represents a key measure by which E2 benefits APOE3
carriers, while harming APOE4 carriers. Because mushroom spines are thought to be
mature spines (Bourne & Harris, 2007; Hayashi & Majewska, 2005), we posit that the
beneficial effects of E2 on memory in E3FADs are linked to this increase in CA1
mushroom spines. Although the same effect of E2 on CA1 basal mushroom spines was
not present in E3/4FADs at the single time point we examined, it may be the case that
the single copy of APOE4 in E3/4FADs slowed the spine remodeling process, which is
highly dynamic, and an E2-facilitated increase in mushroom spines would have occurred
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on a slower time scale in these mice. In addition, low sample size and high within-group
variability in the E3/4FAD groups could also have occluded the potential benefits of E2 on
basilar CA1 mushroom spines in E3/4FADs.
In sum, results from the current study suggest that intrahippocampal E2 infusion
can facilitate memory consolidation and correspondingly increase CA1 apical spine
density in E3FADs and E3/4FADs. Notably, APOE4 genotype had a deleterious effect
on the ability of E2 to enhance memory, and also increased levels of GFAP and ERα in a
manner presumably linked to impaired memory consolidation. In addition, a beneficial
effect of E2 for E3FADs, and a detrimental effect of E2 for E4FADs, on CA1 basal
mushroom spines may account for the respective ability and inability of E2 to enhance
memory in E3FADs versus E4FADs. As with the experiments described in the second
chapter in this dissertation, this study is limited by the examination of protein and spine
density correlates of the mnemonic benefits of E2 at a single time point in EFAD mice.
Therefore, future experiments should examine the kinetics of both protein expression and
dendritic spine density following E2 treatment at multiple time points. Nevertheless, these
data support the notion that E2 treatment can potentially benefit individuals who carry one
copy of the APOE4 allele. More work remains to fully characterize the interactive effects
of E2 and APOE4 genotype in service of developing targeted treatment strategies for AD
patients.
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CHAPTER FIVE: Summary, significance, and future directions
In summary, the findings of this dissertation have added to a growing body of
literature detailing the detrimental effects of APOE4 genotype on memory consolidation,
an effect that is exacerbated in females. Observed APOE4-associated deficits in object
memory consolidation were linked to a detrimental impact of APOE4 on dendritic spine
density in CA1 and in mPFC, and protein alterations in the dorsal hippocampus. We also
showed a detrimental impact of APOE4 and of ovariectomy on anxiety-like behavior in
the open field. Finally, we showed that E2 treatment facilitated memory in ovariectomized
APOE3 carriers and carriers of a single copy each of APOE3 and APOE4, but not in
APOE4 homozygotes. The beneficial effects of E2 were linked to a corresponding
increase in CA1 apical dendritic spine density. By leveraging EFAD mice to model APOEassociated disease risk, we have provided valuable preclinical evidence that sex, APOE
genotype, and estrogens are crucial interacting factors contributing to AD-related risk and
outcomes.
Clinical trial failure rates for AD therapies are astoundingly high, illustrating the
indisputable fact that we urgently need better treatments for AD. Furthermore, targeted
therapies that account for unmodifiable risk factors like APOE status, age, and sex, are
sorely lacking. Thus, much more preclinical work needs to be done to elucidate
relationships among these risk factors and develop interventional approaches to slow and
treat disease progression.
Work from this dissertation illustrates the complex nature of interactions among
variables like APOE genotype and sex, as described in Chapter 2, or APOE status and
estrogens, as described in Chapter 4. Although our primary aim in this dissertation was
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to characterize interactions between APOE genotype and sex, or APOE genotype and
estrogens, we found surprisingly few interactions between these variables. Because we
primarily found effects of APOE genotype, and not interactions between genotype and
sex or genotype and estrogens, several questions remain about how APOE genotype
interacts with these variables in the EFAD model to contribute to disease progression.
One potential future direction that may capture the interactive relationship between
APOE and sex would be to evaluate memory consolidation, dendritic spine density, and
protein alterations at an earlier age in EFADs. Because EFADs develop substantial
pathology by 6 months of age, it may have been the case that potential interactions were
occluded by severe impairment in EFADs of all groups apart from male E3FADs.
Additionally, object tasks may not be the most suitable for detecting APOE x genotype
interactions, because they rely on a single measurement of memory consolidation (time
spent with either the moved or novel object during testing). Although we did not see
differences in Morris water maze performance, we suspect that this is due to the level of
task difficulty. Because EFADs, regardless of sex or genotype, could rapidly learn the
location of the hidden platform in the water maze, a more challenging water maze, with
fewer or less obvious spatial cues, may be better suited for identifying sex x genotype
interactions. Although we hypothesized that APOE genotype and sex might interact to
affect levels of hippocampal proteins we know to be important for memory processes, we
found no interactive effects of APOE genotype and sex on hippocampal protein levels in
the proteins assayed. A quantitative mass-spectrometry approach could be a useful
screening tool to characterize the hippocampal proteome in EFADs and to examine how
it may be affected by genes and sex.
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Our approach towards capturing the interactive effects of APOE status and
estrogens was to examine factors that we know are critical for E2-induced memory
enhancement in young, wild-type mice. However, we were surprised to discover that the
dorsal hippocampal protein expression profile of E2-treated E3FADs and E3/4FAD is
starkly different than that of wild-type mice 5 min following E2 infusion. Therefore, one
potential future direction would be to more fully characterize the time course of E2
activation in EFADs by examining protein expression at multiple time points post-infusion.
Although we assumed E2 would exert its effects in EFADs via the same pathways it
activates in wild type mice, we did not find this to be the case. Therefore, an extremely
useful step would be to infuse E2 into EFAD mice followed by a sequencing approach
such as RNA-seq to identify potential targets of E2 action in EFADs.
Finally, because Golgi staining only captures dendritic spine density at a single
time point, employing chronic in vivo imaging approaches to track changes in dendritic
spine density over time would provide extremely useful information about spine dynamics
in the EFAD model, and could elucidate whether there are differences in spine dynamics
that are impacted by sex, APOE genotype, or estrogens. Although chronic in vivo imaging
of hippocampal spines is made difficult by the depth of the structure, chronic imaging of
cortical spines would still yield novel data about spine dynamics in EFAD mice.
Although rodent models of AD have existed for many years, basic research has
yet to identify what causes AD, and how to prevent it. Because there is no cure, AD places
an enormous burden on healthcare providers, caregivers, and most importantly, patients.
Deaths from AD have increased 145% between the years 2000 and 2019, and during the
COVID-19 pandemic, deaths from AD have increased 16% (Alzheimer’s Association,
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2021). Because APOE4 status and female sex converge to increase AD risk, examining
these factors in concert is key for developing precision medicine approaches to treating
AD. Leveraging the EFAD model to identify crucial interactions among the trifecta of
unmodifiable risk factors for AD: age, APOE4 status, and sex, could ultimately lead to the
identification of targetable biomarkers for precision AD therapeutics.
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